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Abstract
Infectious diseases have had an impact on populations since the beginning of humanity. Despite huge
advances in the fight against these conditions, they continue to be the leading cause of death and
disability for a large portion of the world’s populace. Those most adversely affected predominately live in
the more improvised areas of the developing world. Often treatments are made inaccessible to these
areas due to cost, complicated administration requirements, severe side effects, and / or compound
instability. Even when treatments are available the accelerated development of resistance has created an
urgent need for the creation of new molecules with activity against these microorganisms. This
dissertation focuses on research towards the synthesis and optimization of small novel compounds for
use as antiparasitic leads with the intent of treating infectious diseases.
The first chapter of this manuscript provides an overview of the history, biology and current medicines
available for the tropical diseases: leishmaniasis and malaria. This chapter gives insight into each disease
and illustrates the complications and necessity of novel treatment development.
This introduction is followed by Chapters 2 and 3 describing an investigation towards the development of
antileishmaniasis agents. Research focus on the modification of a compound (SNX 2112) a known heat
shock protein 90 (Hsp90) inhibitor. Hsp90 has been shown as vital to the differentiation of the protozoan
parasite (that causes leishmaniasis) into the infective stage. SNX 2112 was identified as effective against
Leishmania donovani and was the starting point for the development of an analog series. This sequence
of analogs began with the development of a modified quinazoline core to replace the carboxamide top
portion. This modification was developed to reduce overall synthetic steps while maintaining similar
binding features to the original compound. A docking study of one of these analogs identified a

x

hydrophobic pocket in the active site of Hsp90. A series of analogs were created with changes to the
tetrahydroindazole core of the Hsp90 through an ether linkage to attempt to extend into this identified
pocket.
Chapter four covers additional research into the synthesis of modified analogs for malaria treatments.
Including synthesis of novel modified heterocycles of chloroquine, primaquine and mefloquine like
molecules. These analogs maintain the common N-linked side chain of chloroquine and primaquine
while featuring alternative heterocyclic cores which may lead to gains in antimalarial activity or escape
current resistance.

xi

Chapter 1 Infectious Diseases
1.1 Introduction to Infectious Disease
Infectious diseases are classified as illnesses that are products of viruses, bacteria, protozoa, or higher
organisms such as worms.1 These diseases have had an impact on human populations since the
beginning of humanity2 and while huge developments have been made in the fight against them, such as
vaccines and antibiotics, for a large portion of the planet they are still the leading cause of death and
disability.2 These diseases predominate in some of the most impoverished areas of the developing world,
requiring treatments that travel well, are easily administered and inexpensive. The current available
treatments for many of these infectious diseases are expensive or require complicated administration.
These problems make getting treatment difficult for the most vulnerable patients who are suffering from
such diseases.
As travel increases globally and international travel becomes more routine, areas where some infectious
diseases were previously low may begin to see a resurgence in infections.2 Diseases that previously had a
limited geographic distribution are now found globally and infections that spread by person to person
contact can rapidly become widespread. The cost of the effect of infectious disease in United States
alone is over $100 billion a year.1
The development of resistance to available treatments in microorganisms is accelerating and adds a
further complication to the management of infectious diseases. Increased use of antimicrobial agents
has resulted in strong selective pressure on these pathogens and results in the emergence of resistance
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towards these drugs. Most drugs even before being released show some form of population resistance.
Infectious disease drug resistance has become a serious global health problem.3
These factors along with the discovery of new infectious diseases, the recognition that they may play a
part in chronic illness and the lack of research being done for new treatments has created a crisis in the
management of infectious diseases. Research into novel drugs against infectious disease is both vital and
urgent and development of new molecules with activity against the microorganisms that led to these
conditions serves as an important and fertile area of discovery.
1.2: Leishmaniasis
Leishmaniasis is a member of a group of infectious diseases known as neglected tropical diseases (NTD).
NTDs are diverse tropical diseases that affect around a billion impoverished people worldwide. Unlike
malaria, HIV and tuberculosis; these infectious diseases do not receive abundant funding or research
attention. While these conditions may not always kill, they cause disability, developmental delays,
deformity and can contribute to the continued poverty of an area through loss of life, cost of treatments
and productivity and research into treatments is imperative to the health and well-being of a large
portion of humanity.
1.2.1 History of Leishmaniasis
Leishmaniasis is a disease caused by the obligate intramacrophage flagellated protozoa4 of the genus
Leishmania.5 A total of 21 leishmanial species are responsible for the disease which manifests as three
different syndromes: visceral (VL), cutaneous (CL) and mucocutaneous leishmaniasis (MCL).4 The disease
is found in areas of the tropics, subtropics and southern Europe.4 Despite being found in 98 countries,
90% of the new cases diagnosed each year are found in only 13 countries; Afghanistan, Algeria,
Bangladesh, Bolivia, Brazil, Columbia, Ethiopia, India, Iran, Peru, South Sudan, Sudan and Syria.5 While
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the disease mainly affects these countries, overseas travelers, veterans from the Gulf War, and HIV
infected individuals have increased the presence in the US and other countries.4
The disease has been prevalent since the beginning of recorded history. Lesions reminiscent of
leishmaniasis have been described on tablets found from the 7th century BCE.5 In addition, 4 out of 42
Egyptian mummies from a Middle Kingdom tomb in West Thebes (2050-1650 BCE) have been shown to
contain leishmanial mitochondrial DNA.5
The parasite responsible for leishmaniasis was not identified until the early 1900s first by the Scottish
pathologist William Leishman in 1900, who discovered the ovoid bodies of the parasite in smears from
the spleen of a soldier who died while stationed in a town near Calcutta.5 Later that same year an Irish
doctor named Charles Donovan published a paper reporting the finding of bodies similar to those
reported by Leishman in the splenic samples from native Indian subjects with remittent fever and
enlarged spleens.5 In 1903 the medical doctor Ronald Ross published a paper concluding that the ovoid
bodies described by Leishman and Donovan were a novel protozoan organism of a new genus which he
suggested should be named Leishmania donovani and resembled the disease kala-azar (a name used for
VL4).5
1.2.2 Vector
The leishmaniasis protozoa is transmitted by about 70 of the 800 described species of sand-fly.6 Sandflies
are about 2-4 mm in length with a yellowish hairy body,6 they are weak, quiet fliers that rest in dark
moist places and are most often active in the evening and night.4 Both sexes feed on plants but the
female requires a blood meal as part of the process to produce eggs.6 When the female sandflies take
these bloodmeals they can become infected with the protozoa if they bite a diseased mammalian host.4
The female sandflies can then transmit the disease by biting another host.7
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The Leishmania parasite’s lifecycle consists of two principle stages as illustrated in Figure 1.1; the
intracellular amastigote stage within the mammalian host and the flagellated promastigote in the
intestinal tract of the insect vector.6 The promastigote stage begins when the female sand-fly ingests the
amastigotes during a blood meal on an infected mammal. These then transform into the motile
promastigote and multiply in the midgut or hindgut of the insect’s intestinal tract.6 The promastigotes
then migrate to the anterior of the midgut and change into the vertebrate infective form, the metacyclic
promastigotes.6 This form is deposited in the skin of a mammalian host when the insect takes a blood
meal.6 The monocellular phagocytic system of the mammal phagocytoses the promastigotes and the
intracellular parasite changes into the amasigote.6 This amastigote form of the parasite is non-flagellated
and is replicated by mitosis6 in the macrophage phagosomes of the host mammal.4

1.2.3 Symptoms

Figure 1.1 Lifecycle of Leishmaniasis

Clinical representation of the disease depends on where the parasite is localized. The parasite can be
divided into viscerotropic (those that infect the visceral organs and give rise to VL) and dermotropic
4

(infect the dermis and result in CL and MCL).6 Viscerotropic Leishmania species include L. donovani and
L. infantum; almost all others are dermotropic.6 Dermotropic species L. braziliensis and rarely L.
panamensis are known for their secondary mucosal spread that manifests as MCL.6
CL arises when the parasites infect macrophages in the skin. The parasite multiplies and the host cells
then become full of parasites, burst and release the amastigotes to infect neighboring macrophages.5 CL
occurs in the three different forms; localized, diffuse, and mucocutaneous (MCL).5 Localized CL
characteristics include localized skin lesions and ulcers on the exposed parts of the patient’s bodies.
These lesions evolve from papules to nodules before becoming ulcerative lesions, which present with a
central depression and raised border.4 The ulcers can range in severity and can leave permanent scars
when healed.5 The less common diffuse CL results in multiple nodules without ulceration across the
entire body.5
MCL develops months after the initial skin lesion heals when the amastigotes disseminate from the skin
to colonize the mucous membrane. These membranes extend from the nose and mouth to the pharynx
and larynx of the throat. Destruction of the nasal septum, lips, and palate occurs, leading to facial
disfigurement.4-5
There are two types of VL; zoonotic which is transmitted from animal to vector to human and
anthroponotic which is transmitted from human to vector to human. In zoonotic VL, dogs serve as the
main reserve vector for the parasite.7
In VL after transmission of the parasites through the bite of the sand-fly, the amastigotes are spread by
blood circulation to infect the systems of the liver, spleen, bone marrow, lymph nodes and intestines.5
The incubation period once infected is between 2 and 6 months.7 Patients of VL exhibit signs of
persistent systematic infection including fever, fatigue, weakness, weight and appetite loss.7 These
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symptoms last for weeks or months. As a result patients become anaemic, and hypersplenism can
develop leading to abdominal distension and pain.7
1.2.4 Prognosis
Both local CL and diffuse CL can cause multiple painful lesions, which can lead to bacterial infections as
well as disfiguring scars. If left untreated, the patient may develop MCL which can appear during the
initial infection or up to decades after the lesions heal. Adequate treatment for CL is assumed to
decrease the incidence of MCL. Treatment of MCL is more difficult than CL. Treatments required become
more extreme the longer the disease progresses without intervention.4 The destruction of the nose,
mouth, throat, and surrounding tissue due to MCL is debilitating and can lead to the sufferer being
rejected by the community.
Of the forms of leishmaniasis, VL is the most severe. If left untreated the systemic disease is fatal in over
95% of clinical cases.5 These untreated patients generally die from bacterial coinfections, massive
bleeding or severe anaemia.7 With effective treatment, patients begin to feel better within a week,
however most systematic abnormalities do not resolve for weeks or months. Relapses can occur and
patients must be free from symptoms for 6 months to be considered cured.4
1.2.5 Available Treatments
Several treatments are available for the various forms of leishmaniasis. While some of these drugs are
very effective, most suffer from severe side effects, difficult administration and / or high costs, making
their use problematic for the populations most affected by the disease.
Pentamidine treatments were used in the early 1980s7 to treat VL,4 however declining efficacy coupled
with severe side effects and their complicated administration through IM or IV has resulted in the near
abandonment of their use.8
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Miltefosine is an orally available drug for the treatment of VL, which was originally developed as an
anticancer drug.7 Drawbacks to its use as a treatment include a relatively high cost and the requirement
of monitoring patients for severe side effects (including gastrointestinal, hepatic and nephrotoxicity).8 In
addition, it is a known teratogenic and has been shown to induce resistance easily in vitro.7

Figure 1.2 Current Treatments for Leishmaniasis

The standard treatment for VL in most parts of the world are the pentavalent antimonials,
stibogluconate and meglumine antimonate, which have been used since the 1940s.8 These drugs must
be administrated by IV or IM and require a long duration of treatment. The side effects include cardiac
abnormalities, fatigue, and pancreatitis4 and it has been found to be more toxic to patients with
coinfections of HIV.8
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Paromomycin is an aminoglycoside antibiotic with good anti-leishmanial activity against both VL and CL
forms. As a VL treatment it is administered in a parenteral form and as a topical or parenteral form for CL
treatment. It has a relatively high cure rate of 95%, but requires 21 days of treatment and is reasonably
priced.8
Another common treatment for VL, used commonly in India, is amphotericin B deoxycholate. It has
excellent cure rates but requires IV infusions and its side effects, including infusion reactions,
nephrotoxicity, hypokalemia and myocarditis, require close monitoring and hospitalization for 4-5
weeks.7 To combat this drawback, lipid formulations were developed which led to less exposure of the
free drug to the organs, minimizing several serious side effects.8 Liposomal amphotericin B is now the
preferred treatment against VL and the first line of treatment in Europe and the United States. Originally
the cost of these treatments was prohibitive (US $2800 per treatment) but pricing agreements in 2007
between the manufacturer and the World Health Organization has helped to bring prices down for areas
in need (US $200 per treatment).7-8
Due to the inadequacies of the current treatments for leishmaniasis as well as the threat of resistance,
the search and development of novel drugs to combat the parasite are vital.
1.3 Malaria
Malaria is an infectious disease that kills nearly a million children in Africa alone and is one of the top
infectious causes of death worldwide. Despite the availability of current antimalarials, there will always
be a need to continue research into novel treatments due to rapid resistance development.9
Malaria is a disease caused by an infection with protozoan parasites of the genus Plasmodium.10 Five
species are recognized to cause human malaria, although two species result in the majority of infections,
Plasmodium falciparum and Plasmodium vivax.11
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1.3.1 History and Overview
Malaria is an ancient disease, the parasites that led to malaria have been found in mosquitos preserved
in amber from 30 million years ago, long before humans existed.12 The beginning of agriculture resulted
in the consolidation of a large group of people in one area for extended periods of time. This allowed
malaria to begin to become more prevalent and resulted in the disease having a larger impact on human
survival. Some studies suggest that malaria could have played a part in the fall of Greek and Roman
civilization and it was so widespread in Rome that it was known by the term “Roman fever.” The term
malaria itself has origins in medieval Italy where mal’aria meant foul air rising from marshes.13
Currently malaria is most often found in tropic and subtropic areas.11 The disease threatens nearly 40%
of the world’s population,14 with over 200 million cases of malaria worldwide in 2016. Of these cases the
majority (90%) occur within the sub-Saharan African region, and of the 91 countries reporting
indigenous malaria, 15 countries carried 80% of the global malaria burden. There were around 445,000
deaths attributed to malaria globally in 2016, with the African region accounting for 91% of the total.
One species of the parasite, Plasmodium falciparum, is believed to be the cause of 99% of the global
cases of malaria 99%.15
1.3.2 Lifecycle of Malaria
Infection in humans begins when an infected anopheline female mosquito bites a host and the
plasmodia sporozoites (the motile infective form) enter the tissue of the skin. These then migrate to
capillaries and lymphatics before passing to the liver. In the liver the sporozoites invade hepatocytes
(liver parenchymal cells) and develop into merozoites. These merozoites accumulate by asexual
reproduction, and after a period of at least 7 days the hepatocytes (now called schizonts) rupture and
release merozoites into the bloodstream.11 Once in the bloodstream, merozoites invade red blood cells
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and either undergo further asexual reproduction to generate more merozoites or develop into the
immature sexual form (gametocytes) that can then be picked up by another bite of a female mosquito.16
This buildup of merozoites followed by rupture of the schizont resulting in release of the malaria
parasites and erythrocytic material into the bloodstream, induce the onset of symptoms seen in the
disease of malaria.17

Figure 1.3 Lifecycle of Malaria

While contraction of the parasite and infection with malaria is most commonly through mosquito bite,
other routes such as blood transfusion and congenital transmission also occur.11
1.3.3 Symptoms and Prognosis
The beginning symptoms of malaria are common to all the infecting species and typically mimic flu-like
symptoms that include malaise, anorexia, dizziness, headache, backache, nausea, vomiting and a sense
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of chilliness. In the following days the hallmark of malaria, the fever, begins. First the fever is irregular
and temperature rises occur with shivers and chills, however regular periodic fevers may arise depending
on the synchronized rupturing of the schizonts.18
Prognosis depends on the species of malaria parasite, access to effective treatments and the patient’s
overall health and age. When treated quickly, complete recovery often occurs. However, in some cases
severe malaria may develop. Severe malaria occurs when P. falciparum infections are complicated by
serious organ failures or abnormalities in the patient’s blood or metabolism. Complications of severe
malaria may include respiratory failure, acute renal failure, jaundice and hepatic disfunction or severe
anemia. When the central nervous system is affected it is termed cerebral malaria, which when left
untreated is almost always fatal and has an approximate mortality rate of 20% in adults and 15% in
children.17 Pregnant women, children and people with immunosuppression related to HIV are at higher
risk of developing severe malaria.17
1.3.4 Prevention and Treatment
Prevention of malaria can either take the form of preventing infection or preventing the development of
Plasmodia in infected subjects.14 Protection against the mosquito vector can include repellents,
protective clothing, insecticide-impregnated bed nets or use of environmental protection measures such
as insceticides.14 Other methods that protect against the disease of malaria but not against the infection
are termed chemoprophylaxis.14
Historically treatments for malaria were plant derived and during the 17th century the bark from the
cinchona tree was documented as being used to treat malarial fever. The active compound found in the
bark was not isolated until 1820, when quinine was isolated by French chemists. The first commercial
synthesis of this compound, quinine occurred in 1918 followed by the development and synthesis of an
analog, chloroquine in 1946.13
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Figure 1.4 Current Treatments for Malaria
Quinine and its analog, chloroquine, likely react by binding to toxic hematin molecules (a byproduct of
the parasites’ metabolism of blood) and prevents these from transforming into the non-toxic haemozoin
crystal within the mosquito’s gut. The result of this is prevention of parasite detoxification and
consequently the damaging of membranes leading to the destruction of the organism.13
Shortly after the introduction of quinine and chloroquine as treatments for malaria, resistance was
observed, and efforts begun to find alternatives. Primaquine was developed during clinical trials post
WWII and was approved in the 1950s. Primaquine works by exerting its action over the exo-erythrocytic
stages in the liver and interrupts the disease transmission from host to mosquitos. Screening programs in
the 1960s led by the Walter Reed Army Institute led to the development of another third generation of
quinoline.15
Mefloquine was approved for use in 1977 and exerts its action by inhibiting haemozoin formation and
oxidative and glutathione dependent degradation of the heme.13
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Around the same time period as mefloquine development in the US, Chinese research for antimalarials
yielded artemisinin and its derivatives, artesunate and artemether.13 Artemisinin is the active compound
in the Chinese medicinal herb Artemisia annua. This class of antimalarials exhibit rapid onset of action,
broad range of activity on all forms of the parasite, low development of resistance, ease of
administration, and reduced side effects.19
1.3.5 Resistance
Over the past three centuries scientists have been successful in creating new molecules to combat the
occurrence and propagation of malaria. The irrational and extensive utilization of antimalarials leading to
sustained and increased drug pressure and the parasites’ ability to adapt and evade the action of these
antimalarial agents has led to the world being on the precipice of a pandemic. Resistance has been
recorded against almost every anti-malarial drug that is available on the market today. Identifying and
developing new targets and molecules that act upon these targets is desperately needed.13
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Chapter 2: Indazole Analogs
2.1 Introduction
The limitations of current leishmaniasis treatments has highlighted an urgent demand for discovery of
new chemotherapeutic candidates. As an attempt to meet this need our group began efforts to identify
and develop antiprotozoal agents for the treatment of leishmaniasis.
2.1.1 Initial Assay Hit
In order to identify potential hits for the treatment of leishmaniasis, a screening campaign was
conducted using a collection of small molecules in a high throughput axenic amastigote (aa) L. donovani
assay in collaboration with the Kyle research group of the University of South Florida College of Public
Health. One of the compounds that showed high activity was determined to be SNX 2112 (Figure 2.1).
This compound was developed by Serenex as a Heat Shock Protein 90 (Hsp90) inhibitor with potential for
anticancer therapy. In the Kyle axenic amastigote (aa) assay this compound had an IC50 of 0.42 µg/mL
against L. donovani axenic amastigotes. This compound served as the starting point for the development
of analogs for our research into treatments against leishmaniasis.
2.1.2 SNX Compounds
SNX 2112 is a compound developed by the Huang group at Serenex in North Carolina. It was the result of
a structure-based activity (SAR) study conducted on a compound 2.000 (Figure 2.1) which was identified
as a moderate inhibitor of Hsp90 in a screening of a focused compound library. This compound 2.000
showed high selectivity, low molecular weight and represented a novel scaffold. During their SAR studies
they confirmed the primary benzamide and indol-4-one carbonyl as key to activity. They also explored
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the impact of side chains attached to the amido benzene ring and found C-2 ortho alkyl and aryl
substitutions as well as amine linkers (the NH linker may form a stabilizing intramolecular interaction
with the amide carbonyl group) of the side chains enhanced Hsp90 binding affinity. In addition, their
work showed that moving the C-2 indolone methyl group to the C-3 position increased activity and that
the gem-6,6-dimethyl groups were imperative to activity.

Figure 2.1 – SNX 2112 Structure and Original Structure Identified by Huang Group
This systematic exploration of analogues led to the creation of SNX 2112,1 which was entered into
clinical trials and showed growth inhibition and apoptosis-inducing activity in many human cancer cells.
However its development was stopped due to ocular toxicity in both animal and phase I studies.2
2.1.3 Introduction to Hsp90
The compound SNX 2112 was developed as an inhibitor of the cellular chaperone protein Hsp90.
Chaperone proteins are a class of proteins that bind and stabilize other proteins inside the cell. These
proteins provide an environment in which their client proteins are able to adopt their proper tertiary
structure more efficiently.3 Chaperone proteins can also prevent incorrect folding interactions and aid in
the refolding. This class of proteins are vital to the cells, especially during times where environmental
changes may lead to protein damage.3 The category of chaperones called heat shock proteins were first
described in 1962 when it was observed that their synthesis increased after a drastic increase in heat
(termed heat shock). This rise contrasted with the reduced synthesis of other cellular proteins. The
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synthesis of these heat shock proteins can also be modulated by other stresses in which conditions may
lead to protein denaturation and the need for refolding may occur.4 Heat shock proteins differ in their
location as well as function and are classified into several families according to their size, for example:
Hsp90, Hsp70, Hsp60 and Hsp40.4
One of the most abundant cellular chaperone proteins is Hsp90, which accounts for 1-2% of the total
protein in unstressed cells and 4-5% in stressed cells.4 Hsp90 is a homodimer with each monomer
containing three subunits,5 highly conserved N-terminal and C-terminal domains connected to each
other by a charged linker. This linker can vary in length or composition by species or isoform.6 The Nterminus is the site of ATP binding and is unique in its shape from other ATP binding proteins.5
Chaperoning activity of Hsp90 requires the binding and hydrolysis of ATP at this site and binding alters
the conformational state allowing interaction with client proteins and co-chaperones.4
2.1.4 Hsp90 in Cancer
Hsp90 acts as a chaperone for almost 50 proteins that play important roles in the cell cycle.5 The
functions of these proteins include cell signaling, proliferation and cell survival. Hsp90’s role in the
management of such vital proteins led it to be considered as a potential target for cancer therapy. The
particularly stressful environment of the cancer cell leads to the expression of Hsp90 being up to 3 times
higher than in noncancerous cells and this overexpression is also correlated to a poor prognosis.5 Hsp90
stabilizes wild and mutant forms of its client proteins and may allow tumor cells to tolerate otherwise
lethal mutations, making it a theoretical target for anticancer chemotherapies. In addition cancer cells
have been shown to be more sensitive to Hsp90 inhibitors than non-transformed cells and tumor cells
can be selectively killed at doses that are nontoxic to normal cells.5
This has led to the development of several Hsp90 inhibitors. The natural products radicicol1 and
geldanamycin (GA) were both found to be potent Hsp90 inhibitors.2 GA was found to bind to an ATP
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pocket in the N-terminal domain of Hsp90, however its toxicity limited its use, leading to the formation
of several analogs. 17-Allylamino-17-demethoxygeldanamycin (17-AAG,) an analog of GA, was the first
Hsp90 inhibitor to enter clinical trials, where it showed good tolerability and efficacy but suffered from
low solubility and limited bioavailability.1 These drawbacks have catalyzed efforts to identify novel
compounds with improved pharmacological properties to be used as Hsp90 inhibitors.
2.1.5 Hsp90 in Parasites
In addition to cancer therapies Hsp90 has been identified as a target for antiparasitic drug discovery.
Several pathogenic parasites such as Trypanosoma, Leishmania, Toxoplasma and Plasmodium have been
known to use Hsp90 during important stages in their life cycles.5 The life cycles of these organisms often
alternate between different species of hosts, and during these transitions the parasites encounter
several environmental changes including a rise in temperature and changes in pH.5, 7
In Leishmania, Hsp90 comprises of almost 2.8% of the total cellular protein, making it one of the most
abundant proteins, and has been shown to play a role in the transition from the insect to the
mammalian stage.8 The rise of temperature during this transmission disturbs the homeostasis of the cell
and could be considered a signal to initiate cellular differentiation. This transformation from
promastigote to amastigote form has been shown to be dependent on Hsp90 and this link has been
shown in culture using Hsp90 inhibitors.7 These connections between Hsp90 and parasites may suggest
why SNX 2112, an Hsp90 inhibitor, exhibited activity in the Kyle aa assay.
2.1.6 Initial Analogs
To begin our exploration into SNX 2112 analogs as antileishmanial compounds, our group synthesized
2.001 (Figure 2.2), an analog of SNX 2112, from commercially available dimedone. This was done to not
only verify the original hit but also to begin exploring analogs for lead optimization. To create this analog,
we chose to eliminate the stereochemistry of the 4 hydroxylcyclohexylamino side chain in favor of a
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simplified 3-methyloxypropan-1- amine side chain. This alternative group contained the required
hydrogen bond acceptor and donor groups without stereochemistry but also possessed the flexibility to
achieve the required confirmation. This analog showed activity in the aa assay and formed the starting
point of further analog development. We also synthesized analog 2.002 which lacks the 6,6 dimethyl
groups. This compound showed a complete loss of activity, confirming that these groups were essential
to antileishmanial activity.

Figure 2.2 – Initial Analogs
2. 2 Quinazoline
In order to eliminate redundant steps, we sought to simplify the synthesis. We proposed the use of a
quinazoline top portion (as shown on compound 2.003) of the molecule as a viable substitute to the
carboxamide in compounds 2.001 and 2.002. This replacement would eliminate two steps (Figure 2.3) of
the synthesis after the introduction of our diversity to the tetrahydro indazole. This change resulted in a
more streamlined, convergent synthesis which would allow multiple analogs to be made quickly,
therefore minimizing the use of extra resources and time.
The proposed quinazoline top portion mimics the previous analogs binding motif with the required
nitrogens, which were previously established as vital for activity. The synthesis of the novel quinazoline,
in contrast to the original analog, requires zero steps after the cyclization reaction to reach the final
product (Figure 2.4). This would allow diversity to be introduced at the desired position by making
changes to the triketone.
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Figure 2.3 – Comparison of Routes
2.2.1 Synthesis
The quinazoline synthetic route (Scheme 2.1) began by treating 2,4-difluorobenzonitrile with
formamidine acetate in the presence of sodium hydride to yield 2.007, which was then treated with
hydrazine to obtain 2.008. This product was then combined with the triketone 2.006, previously made by
other researchers in our group, and treated with acetic acid in methanol to yield compound 2.003.9
Compared to the original analog created in our group (2.001), this compound showed reduced activity
with an IC50 of 2.4 µg/mL in the aa assay.
Despite this decreased activity, the result demonstrated that large hydrophobic groups could be
tolerated at this position without losing all inhibitory activity. In addition, it confirmed that we could
create a quinazoline series of analogs with retention of some activity, thus allowing us to pursue the
more efficient synthesis. We could use 2.003 as a baseline to compare the activity of new analogs. If one
of these analogs was particularly active, we could then synthesize the related analog with the original
carboxamide top portion.
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Scheme 2.1 – Synthesis of a Quinazoline Analog

Reagents and conditions: (a) Ac2O, iPr2NEt, DMAP, CH2Cl2 (89%); (b) formamidine acetate, NaH (32%);
(c) NH2NH2 (93%); (d) 2.006, AcOH, EtOH (55%)

2.3 Docking Studies
Compound 2.003 with its more rigid structure and restricted rotatable bonds (versus previous analogs)
was a great candidate for computational docking into the active site of Hsp90. We used available
coordinates (3DOB) for a cocrystal in AutoDock 1.5.6 and performed a calculation of our compound
2.003 docked in human Hsp90. This data illuminated some interesting interactions of our molecule and
its target. Figure 2.4 shows the compound within the binding site of Hsp90 and shows some of the vital
intermolecular interactions, such as the two nitrogens of the quinazoline ring participating in hydrogen
bonding interactions with Tyr139 and Asp93 of the protein. Other views reveal a channel within the
protein into which the two geminal methyl groups of 2.003 project. This channel demonstrated a
potential hydrophobic pocket that we could further exploit for activity or selectivity.
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Figure 2.4 – Docking studies of 2.010

2.4 Cyclopropyl Analogs
As a next step after the synthesis of the original dimethyl with the analog 2.003, we undertook the
synthesis of a cyclopropyl analog (Scheme 2.2). Our synthesis began with a Wittig reaction by treating 1ethoxycyclopropoxy trimethylsilane (2.012) with a triphenylphosponium ylide (2.011) to produce the
α,β-unsaturated ketone 2.013, to which we then performed a Michael-Claisen reaction followed by
hydrolysis and decarboxylation to yield 2.014. This diketone was then acetylated10 to yield the triketone
2.015 which then was used in both the original and quinazoline routes.
The original carboxamide top portion synthesis utilized chemistry established by previous work done by
others in our group.11 This route (Scheme 2.3) began by treating commercially available 2-bromo-4fluoro-benzonitrile with hydrazine in order to perform a nucleophilic aromatic substitution of the
fluorine,12 obtaining compound 2.018, which was then treated with the cyclopropyl triketone 2.015 and
acetic acid to perform the cyclization and yield 2.019.10 A Buchwald-Hartwig amination was performed to
install the 3-methoxypropan-1-amine side chain on 2.020, followed by hydration of the nitrile with H2O2
and sodium hydroxide to yield the final desired analog 2.021.12
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Scheme 2.2 – Synthesis of a Quinazoline Cyclopropyl Analog

Reagents and conditions: (a) pTsOH (44%); (b) (i) CH2(CO2Me)2, NaOMe (ii) KOH, HCl (78%); (c) DMAP,
DCM, Ac2O, iPr2NEt (50%); (d) 2.009, AcOH, EtOH (71%)

Scheme 2.3 – Synthesis of the Cyclopropyl Benzamide Analog

Reagents and conditions: (a) NH2NH2, THF (85%); (b) 2.015, MeOH, AcOH (86%); (c) H2N(CH2)3OMe,
Pd(OAc)2, DPPF, NaOtBu, Toluene, mW, 120 oC (39%); (d) NaOH, H2O2, EtOH, 100 °C (6%)
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2.5 Conclusions
We successfully synthesized analogs of our target molecule with an alternate quinazoline top portion.
This top portion mimics the binding motifs of the original molecule SNX2112 while reducing the overall
synthesis by two steps. This reduction will allow for the introduction of diversity and the creation of
multiple analogs to occur in a final step. In addition, we created two cyclopropyl analogs with each top
portion that imitates the dimethyl of SNX2112. From this starting point we began our work into
synthesizing diverse ether analogs to further explore the SAR of this molecule.

2.6 Experimental Section

All reagents and solvents, unless specifically stated, were used as obtained from their commercial
sources without further purification. Air and moisture sensitive reactions were performed under an inert
atmosphere using either argon or nitrogen in a previously oven-dried or flame-dried reaction flask, and
addition of reagents were done using a syringe. Dry tetrahydrofuran (THF) was obtained via distillation
from sodium benzophenone ketyl. All microwave (mW) reactions were carried out with an Anton Paar
monowave 300 instrument. Thin layer chromatography (TLC) analyses were performed using 200 µm
pre-coated Sorbtech fluorescent TLC plates and spots were visualized using UV light and/or by staining
with different stains including iodine vapor, ceric ammonium nitrate, acidic vanillin or acidic
anisaldehyde. Analytical LCMS data was obtained using an Agilent 1100 HPLC/MSD system equipped
with a diode array detector running a MeOH/H2O gradient. Purification of compounds was carried out
using Sorbtech silica gel (60Å porosity, 40-63 µm particle size) in fritted medium pressure liquid
chromatography (MPLC) cartridges and eluted with Thomson Instrument SINGLE StEP pumps. Reverse
phase preparative HPLC (prepHPLC) purification was achieved on an Agilent preparative 1200 LC/6120B
equipped with a single quadrupole mass spectrometer detector.
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High resolution mass spectral (HRMS) data was performed on an Agilent 6540 Ultra-High-Definition
(UHD) Liquid chromatography quadrupole time-of-flight mass spectrometry (LC/QToF-MS) with
electrospray ionization (ESI) detection. Nuclear magnetic resonance (NMR) spectrometry was run on a
Varian Inova 500 MHz, Varian Inova 400 MHz or Varian Mercury 400 MHz spectrometer and data was
processed using the ACD/NMR Processor program. Chemical shifts are reported in ppm with residual
solvent peaks referenced as internal standard. All compounds were determined to be >95% pure by
HPLC analysis and further confirmed by NMR analysis.

General Synthetic Procedures:

7-Fluoro-quinazolin-4-amine : To a solution of 2,4-difluorobenzonitrile (1.0 g, 7.2 mmol) and
formamidine acetate (3.0 g, 29 mmol) in 50 mL dimethylacetaminde was slowly added NaH (60%
suspension in mineral oil, 2.3 g 58 mmol). The solution was heated to 120 °C overnight. The cooled
reaction was then poured into a saturated solution of NaHCO3 and the aqueous phase was extracted
with ethyl acetate (3X). The combined organic layers were washed with brine, dried over MgSO4 and
concentrated under reduced pressure until dry. The crude material was purified by silica column
chromatography eluted with 10% methanol in dichloromethane to yield 2.008 as a light reddish-tan solid
(0.07244 g, 62%). 1H NMR (DMSO-d6, 400 MHz): δ 8.35 (s, 1H), 8.25 - 8.32 (m, 1H), 7.84 (br. s., 2H), 7.34 7.41 (m, 2H).
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7-Hydrazino-quinazolin-4-ylamine : Hydrazine (16 mL, 510 mmol) and 2.008 (0.40 g, 2.5 mmol) were
combined to give an orange suspension and stirred overnight at room temperature. The hydrazine was
removed under reduced pressure and the solution was lyophilized to dryness. The dry solid was
triturated with 2-propanol for 30 minutes and collected with filtration to yield 2.009 as a light brown
solid (0.41 g, 95%). 1H NMR (CD3OD, 400 MHz): δ 8.19 (s, 1H), 7.83 (d, J=9.03 Hz, 1H), 6.97 (dd, J=2.20,
9.08 Hz, 1H), 6.91 (d, J=2.15 Hz, 1H).

1-(4-Aminoquinazolin-7-yl)-3,6,6-trimethyl-6,7-dihydro-1H-indazol-4(5H)-one : To 2.009 (17.2 mg, 0.1
mmol) and 2-acetyl-5,5-dimethylcyclohexane-1,3-dione (26 mg, 0.14 mmol) in methanol was added
acetic acid (1 µl, 0.02 mmol) and the solution was stirred at room temperature for 3 days. The reaction
was concentrated and purified using HPLC to yield 2.003 as a white solid (17.2 mg, 54.5%). 1H NMR
(DMSO-d6, 500 MHz): δ 8.47 - 8.60 (m, 1H), 8.36 - 8.46 (m, 1H), 7.99 (br. s., 2H), 7.79 - 7.85 (m, 2H), 4.06 4.24 (m, 1H), 2.49 (s, 3H), 2.41 (s, 2H), 1.09 (s, 6H). 13C NMR (DMSO-d6, 126 MHz): δ 193.5, 162.0, 157.0,
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150.5, 150.5, 149.4, 142.0, 125.9, 121.1, 120.2, 117.2, 113.5, 52.2, 36.8, 35.9, 28.2, 13.6. HRMS m/z: [M
+ H]+ calc’d for C18H19N5O 322.1668; Found 322.1670.

6-Acetylspiro[2.5]octane-5,7-dione : Into 5 mL of CH2Cl2 was added 2.014 (0.30 g, 1.8 mmol) and DMAP
(0.03 g, 0.6 mmol) and Hunig's base (0.35 mL, 2.0 mmol). A solution of acetyl chloride (0.15 mL, 2.03
mmol) in DCM was added dropwise and the mixture was heated to reflux for 2 hours. The mixture was
concentrated then portioned between 5 mL of 1 N HCl and 15 mL of 2:1, hexane / ethyl acetate. The
organic layer was washed with brine, dried over MgSO4, filtered and concentrated to yield 2.015 as a
white solid (0.1661 g, 50.0%). 1H NMR (CDCl3, 400 MHz): δ 18.15 (s, 1H), 2.58 (s, 4H), 2.50 (s, 2H), 2.32 (s,
3H), 0.45 (d, J=0.54 Hz, 4H). 13C NMR (CDCl3,101 MHz): δ 202.7, 198.6, 195.0, 113.3, 47.6, 42.4, 28.4,
13.1, 10.7.

1'-(4-Aminoquinazolin-7-yl)-3'-methyl-1',7'-dihydrospiro[cyclopropane-1,6'-indazol]-4'(5'H)-one : Using
conditions identical to those described above for compound 2.010, 2.015 was converted to 2.016 as a
white solid (0.1108 g, 70.9%). 1H NMR (500 MHz, DMSO-d6): δ 8.42 (s, 1H), 8.35 (d, 1H, J=8.8 Hz), 7.91
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(br s, 2H), 7.7-7.8 (m, 2H), 3.04 (s, 2H), 2.49 (br s, 3H), 2.34 (s, 2H), 0.4-0.5 (m, 4H). 13C NMR (126 MHz,
DMSO-d6): δ 193.5, 162.0, 157.0, 151.5, 150.7, 149.6, 142.0, 125.8, 120.9, 120.1, 118.7, 113.5, 47.5,
32.8, 18.0, 13.7, 11.3. HRMS m/z: [M + H]+ calc’d for C18H17N5O 319.1511; Found 319.1541.

2-Bromo-4-hydrazineylbenzonitrile : Into a clean, dry round-bottomed flask was added 2-bromo-4fluorobenzonitrile (2.6 g, 13 mmol) in 10 mL dry THF under argon. To this was slowly added hydrazine (5
mL, 200 mmol) then the reaction was allowed to warm to room temperature and stir for 16 hours. A
clear solid formed and the reaction was washed with a saturated solution of sodium bicarbonate until
the pH was approximately 8.5. The organic layer was evaporated under reduced pressure and the white
solid was washed with 1L of water and collected on a fritted glass funnel. The solid was washed with 50
mL of diethyl ether, which was then combined with the solid and dried under reduced pressure. The
sample was further dried on the lyophilizer to yield 2.018 of a fluffy white solid (2.4 g, 85 %). 1H NMR
(DMSO-d, 500 MHz): δ 8.04 (s, 1H), 7.47 (d, J= 8.8 Hz, 1H), 7.06 (d, J=1.5 Hz, 1H), 6.69 - 6.77 (m, 1H), 4.38
(s, 2H) ppm. 13C NMR (DMSO, 126 MHz): δ 156.7, 135.4, 125.9, 119.6, 113.6, 110.4, 98.5 ppm.
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2-Bromo-4-(3'-methyl-4'-oxo-4',7'-dihydrospiro[cyclopropane-1,6'-indazol]-1'(5'H)-yl)benzonitrile :
2.015 (0.17 g, 0.92 mmol) and 2.018 (0.22 g, 1.0 mmol) were combined in 10 mL of methanol and
treated with acetic acid (0.02 mL, 0.3 mmol) and stirred at rt for two days. The reaction was
concentrated under reduced pressure. The crude material was purified by silica column chromatography
eluted with 2:1 hexanes / ethyl acetate to yield 2.019 as a yellow-white solid (0.28 g, 86 %). 1H NMR
(CDCl3, 400 MHz): δ 7.91 (d, 1H, J=1.8 Hz), 7.73 (d, 1H, J=8.4 Hz), 7.54 (dd, 1H, J=1.9, 8.5 Hz), 2.85 (s, 2H),
2.53 (s, 3H), 2.38 (s, 2H), 0.5-0.6 (m, 4H). 13C NMR (CDCl3, 101 MHz): δ 193.1, 151.6, 149.9, 142.6, 134.9,
126.9, 126.3, 121.0, 119.8, 116.5, 114.2, 47.4, 33.8, 17.6, 13.4, 11.9.

2-((3-Methoxypropyl)amino)-4-(3'-methyl-4'-oxo-4',7'-dihydrospiro[cyclopropane-1,6'-indazol]-1'(5'H)yl)benzonitrile : In a microwave vial was added 2.019 (200 mg, 0.561 mmol), diacetoxypalladium (22.69
mg, 5.05 µmol), DPPF (32.6 mg, 0.04 mmol), and sodium 2-methylpropan-2-olate (113 mg, 1.18 mmol) in
toluene (5 mL). 3-Methoxypropan-1-amine (229 µL, 2.25 mmol) was added and the solution was heated
in a microwave at 110 °C for 15 minutes. The reaction was concentrated under reduced pressure then
purified by column chromatography (silica gel, eluent: hexanes/ethyl acetate 5:2) to yield 2.020 as a
white solid (0.0789 g, 76 %). 1H NMR (CDCl3, 400 MHz): δ 7.43 (d, 1H, J=8.3 Hz), 6.81 (s, 1H), 6.66 (br d,
1H, J=8.0 Hz), 5.48 (br s, 1H), 3.54 (t, 2H, J=5.4 Hz), 3.3-3.4 (m, 5H), 2.81 (s, 2H), 2.54 (s, 3H), 2.37 (s, 2H),
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1.94 (quin, 2H, J=5.8 Hz), 0.4-0.6 (m, 4H). 13C NMR (CDCl3, 101 MHz): δ 193.4, 151.4, 150.6, 149.6, 143.4,
133.7, 119.1, 117.2, 110.1, 104.8, 94.8, 71.2, 58.8, 47.6, 42.0, 33.7, 28.6, 17.7, 13.4, 11.6.

2-((3-Methoxypropyl)amino)-4-(3'-methyl-4'-oxo-4',7'-dihydrospiro[cyclopropane-1,6'-indazol]-1'(5'H)yl)benzamide : In a microwave vial were added 2.020 (0.07 g, 0.2 mmol), 0.21 mL 1M aqueous NaOH,
0.1 mL H2O2 (30 % by weight in H2O), 2.6 mL DMSO, and 2.6 mL ethanol and the mixture was heated for
10 minutes in a microwave reactor at 100 °C. The solution was then washed with water and extracted
with ethyl acetate (3 x 50 mL). The organic layer was dried over Na2SO4 and concentrated under reduced
pressure. The crude product was loaded on silica and eluted on a silica gel column with 20-50% ethyl
acetate in hexanes to yield 2.021 as a white solid (0.03 g, 40 %).1H NMR (CDCl3, 500 MHz): δ 7.45 (d, 1H,
J=8.4 Hz), 6.8-6.8 (m, 1H), 6.6-6.7 (m, 1H), 5.5-5.8 (m, 2H), 3.50 (t, 2H, J=5.9 Hz), 3.3-3.4 (m, 2H), 3.30 (t,
2H, J=6.8 Hz), 2.84 (s, 2H), 2.56 (s, 3H), 2.39 (s, 2H), 1.93 (quin, 2H, J=6.4 Hz), 0.4-0.6 (m, 4H). 13C NMR
(CDCl3, 126 MHz): δ 193.5, 171.1, 151.1, 150.3, 149.6, 142.8, 129.4, 112.0, 108.7, 106.0, 70.2, 58.7, 47.7,
40.2, 33.6, 29.2, 17.7, 13.5, 11.6. HRMS m/z: [M + H]+ calc’d for C21H27N4O3 382.2083; Found 382.2082.

2.6 List of References
1.

Huang, K. H.; Veal, J. M.; Fadden, R. P.; Rice, J. W.; Eaves, J.; Strachan, J.-P.; Barabasz, A. F.;

Foley, B. E.; Barta, T. E.; Ma, W.; Silinski, M. A.; Hu, M.; Partridge, J. M.; Scott, A.; DuBois, L. G.; Freed, T.;

30

Steed, P. M.; Ommen, A. J.; Smith, E. D.; Hughes, P. F.; Woodward, A. R.; Hanson, G. J.; McCall, W. S.;
Markworth, C. J.; Hinkley, L.; Jenks, M.; Geng, L.; Lewis, M.; Otto, J.; Pronk, B.; Verleysen, K.; Hall, S. E.,
Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally
active antitumor agents. J. Med. Chem. 2009, 52 (14), 4288-4305.
2.

Wang, S.; Wang, X.; Du, Z.; Liu, Y.; Huang, D.; Zheng, K.; Liu, K.; Zhang, Y.; Zhong, X.; Wang, Y.,

SNX-25a, a novel Hsp90 inhibitor, inhibited human cancer growth more potently than 17-AAG. Biochem.
Biophys. Res. Commun. 2014, 450 (1), 73-80.
3.

Csermely, P.; Schnaider, T.; Soti, C.; Prohaszka, Z.; Nardai, G., The 90-kDa molecular chaperone

family: structure, function, and clinical applications. A comprehensive review. Pharmacol. Ther. 1998, 79
(2), 129-168.
4.

Goetz, M. P.; Toft, D. O.; Ames, M. M.; Erlichman, C., The Hsp90 chaperone complex as a novel

target for cancer therapy. Ann Oncol 2003, 14 (8), 1169-76.
5.

Patki, J. M.; Pawar, S. S., HSP90: Chaperone-me-not. Pathol. Oncol. Res. 2013, 19 (4), 631-640.

6.

Pearl, L. H.; Prodromou, C., Structure and in vivo function of Hsp90. Curr. Opin. Struct. Biol.

2000, 10 (1), 46-51.
7.

Roy, N.; Nageshan, R. K.; Ranade, S.; Tatu, U., Heat shock protein 90 from neglected protozoan

parasites. Biochim. Biophys. Acta, Mol. Cell Res. 2012, 1823 (3), 707-711.
8.

Wiesgigl, M.; Clos, J., Heat shock protein 90 homeostasis controls stage differentiation in

Leishmania donovani. Mol. Biol. Cell 2001, 12 (11), 3307-3316.
9.

Huang, K. H.; Veal, J.; Barta, T.; Smith, E. D.; Ma, W.; Ommen, A. Isoquinoline, quinazoline and

phthalazine derivatives as HSP90 inhibitors and their preparation, pharmaceutical compositions and use
in the treatment of proliferative diseases. WO2008024977A2, 2008.
10.

Haystead, T.; Hughes, P. F. Compounds and methods for targeting HSP90. US20150191471A1,

2015.

31

11.

Kanwar, A.; Eduful, B. J.; Barbeto, L.; Carletti Bonomo, P.; Lemus, A.; Vesely, B. A.; Mutka, T. S.;

Azhari, A.; Kyle, D. E.; Leahy, J. W., Synthesis and activity of a new series of antileishmanial agents. ACS
Medicinal Chemistry Letters 2017, 8 (8), 797-801.
12.

Huang, K. H.; Eaves, J.; Veal, J.; Barta, T.; Geng, L.; Hinkley, L.; Hanson, G. Tetrahydroindolone

and tetrahydroindazolone derivatives and their preparation, pharmaceutical compositions, and use for
treatment of diseases related to cell proliferation. WO2006091963A1, 2006.

32

Chapter 3 C-Linked Analogs
3.1 Introduction
After the successful synthesis of our quinazoline analog we began synthesis of a series of carbon-linked
analogs. We hoped to explore the hydrophobic pocket found through our docking studies with these
analogs. In order to accomplish this, we proposed using an ether linkage to attach various hydrocarbon
chains. This would allow us to extend various lengths and configurations of hydrophobic chains into this
space.
3.1.1 Protecting Groups and Convergent Synthesis
In order to achieve these ether-linked analogs, we looked to create an intermediate with a primary
alcohol in the desired position. However, since hydroxyl groups are reactive to conditions used in the
synthesis, we proposed the use of a protecting group. Ideally, we could create an advanced analog that
when deprotected could then be used to produce the final ether analogs in one step. This approach
would allow us to generate multiple diverse compounds as efficiently as possible. We proposed the use
of the quinazoline analog with a -CH2OH in the place of the di-methyl groups as a precursor for this
divergent synthesis. A benzyl group was chosen as our protecting group based on its ability to be
removed through conditions that should be compatible with the other functionality of the molecule.
3.1.2 Synthesis of Benzyl Protected Analog 3.007
As outlined in Scheme 3.1 the synthesis of a benzyl-protected analog 3.007 began with the Birch
reduction of 3,4,5-trimethoxybenzoic acid, followed by reduction of the carboxylic acid using LiAlH4 to
obtain the alcohol 3.003.1 This newly formed alcohol was then protected as benzyl ether 3.0042 and the
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vinyl methyl ethers were hydrolyzed to generate the diketone.2 Compound 3.005 was subsequently
acetylated3 to achieve the triketone 3.006 which was used in the cyclization reaction with the
quinazoline4 to yield benzyl-protected analog 3.007.
Scheme 3.1 – Synthesis of Benzyl-Protected Quinazoline

Reagents and conditions: (a) Na, NH3 (liq), MeOH, -78 °C, (99%); (b) LiAlH4, THF (82%); (c) NaH, BnBr,
THF (30%); (d) HCl (aq) (81%); (e) DMAP, DCM, Ac2O, iPr2Net (84%); (f) MeOH, AcOH (93%)

In addition to the benzyl-protected analog, we concurrently worked on a synthesis of a methyl ether
analog. This was undertaken in order to confirm that other ether-linked analogs with the quinazoline top
portion could be synthesized. We also wanted to verify that different analog functionality could be
tolerated with a retention of anti-leishmanial activity. This synthesis (Scheme 3.2) followed the same
steps and conditions of the benzyl analog except for methyl ether 3.008 was created from the reduced
alcohol 3.003 instead of the benzyl ether.
For each of the quinazoline analogs we also created (both the methyl ether and benzyl ether) analogs
using the corresponding triketone and the initial carboxamide top portion. These syntheses (Scheme 3.3)
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followed those already outlined in Scheme 2.4 by substituting the corresponding triketone in step b
without difficulties to yield compounds 3.016 and 3.017.
Scheme 3.2 – Synthesis of Methyl Ether Quinazoline

Reagents and conditions: (a) NaH, MeI, THF (80%); (b) HCl (aq) (85%); (c) DMAP, DCM, Ac 2O, iPr2NEt
(39%); (d) 2.009, MeOH, AcOH (31%)

Scheme 3.3 – Synthesis of Benzyl and Methyl Ether Carboxamide

Reagents and conditions: (a) MeOH, AcOH; (b) 3-methoxypropan-1-amine, NaOtBu, Pd(OAc)2, DPPF,
100 °C; (c) NaOH, H2O2, EtOH, 100 °C
35

3.1.3 Removal of Benzyl Protecting Group from 3.007
Once we obtained 3.007 and 3.017, we began our attempts at removing the benzyl group to expose the
alcohol, which could then be used as a starting point to making ether-linked analogs. We anticipated that
the deprotection of this group would have been straightforward and thus we began by using standard
hydrogenation conditions. We treated 3.007 with atmospheric hydrogen under argon in the presence of
Pd/C.5 When these conditions yielded no product and no change in the molecule, we increased the
pressure of the reaction using a Parr apparatus. We also attempted to increase the temperature of the
reaction. These more aggressive conditions proved to have no effect. Suspecting that the catalyst might
be compromised or not ideal, we attempted other conditions and alternative sources of catalysts. These
conditions included the use of Raney Nickel, as well as multiple sources of each catalyst. We also tried
multiple different sources of hydrogen including H2 gas from different tanks as well as several different
hydrogenators.
None of the conditions removed the benzyl group or affected the analog. While searching for conditions
for deprotection with similar functional groups we discovered a paper using FeCl3.6 We first attempted
these conditions on the intermediate triketone and when that proceeded well, we treated 3.007 with
the same conditions (Scheme 3.4).
Scheme 3.4 – Benzyl Removal and Decomposition

Reagents and conditions: (a) FeCl3, DCM
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Despite finding evidence for the debenzylation of the triketone and compound 3.018 by mass
spectrometry, we found that 3.018 decomposed quickly after deprotection. We observed mostly
aromatic peaks and almost no aliphatic peaks by proton NMR. This data would suggest the enol form of
3.018 may have aromatized. The method by which this might have happened is not entirely clear,
however water may have been eliminated (3.018a), which would allow the alkene to migrate to form an
aromatic ring (3.018b).

3.2 Modified Quaternary Carbon Series
Since we suspected that the decomposition of 3.018 may have been due to aromatization, we
considered blocking this by creating a quaternary carbon at this position. By replacing the hydrogen with
a methyl group (3.019), we would not only block this suspected decomposition but would also mimic the
original compounds SNX 2112 and 2.003.

Figure 3.1 – Comparison of Initial Analogs and Quaternary Analog
3.2.1 Dieckmann Cyclization
We began the synthesis of 3.019 by looking back at one of the previous routes used to create the
cyclopropyl analog. This synthesis utilized a Dieckmann cyclization of an α,β-unsaturated ketone to
create the diketone 2.014 as an intermediate in the synthesis. Since this compound was analogous to the
diketone 3.020 needed to create 3.019 we hoped to follow a similar route. This path (Figure 3.2) started
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with a Wittig reaction of a benzyl-protected ether 3.023 and a triphenylphosphonium ylide to obtain
3.021. This ketone could then be treated under Dieckmann cyclization conditions to yield the diketone
3.020 which could then be used to complete the synthesis.

Figure 3.2 – Retrosynthesis Using Dieckmann Cyclization
This synthesis as shown in Scheme 3.5 began with protection of the alcohol of commercially available
glycidol (3.024) with a benzyl ether followed by the opening of the epoxide7 to yield a secondary alcohol.
3.026 was then oxidized to the ketone 3.023.8
Scheme 3.5 – Attempted Synthesis of Alpha Beta Unsaturated Ketone 3.021

Reagents and conditions: (a) NaH, BnBr, DMSO (55%); (b) LiAlH4, THF (95%); (c) PCC, DCM (78%)
Next, we attempted a Wittig reaction to install the α,β-unsaturated ketone; unfortunately, this was
unsuccessful. After the failure of the Wittig, we considered an alternate route involving a Weinreb amide
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(Scheme 3.6). We first performed the Horner-Wadsworth Emmons reaction on ketone 3.023 followed by
conversion to the Weinreb amide to yield 3.028. On this product we performed a Grignard reaction with
methyl magnesium bromide to create ketone 3.029.9 This was then treated to the Dieckmann cyclization
conditions used previously to create 2.014. Unfortunately, endeavors at getting this reaction to work
were unsuccessful and after multiple attempts using different procedures, we decided to pursue a
different synthetic route to obtain the desired diketone 3.020.
Scheme 3.6 – Attempted Synthesis of Diketone 3.020

Reagents and conditions: (a) Triethyl phosphonoacetate, NaH, THF (32%); (b) iPrMgCl, THF, CH3NHOCH3
· HCl (96%); (c) CH3MgBr, THF, NH4Cl (76%)

3.2.2 Birch Alkylation with tert-Butyl Ester
Given the difficulty that we experienced performing the cyclization, we considered instead installing the
methyl group by attempting a Birch alkylation. This reaction would use similar conditions to the
previously used Birch reduction in Scheme 3.2 but would be quenched with an alkylating agent (methyl
iodide) instead of a proton source. Initial attempts at the alkylation using the initial carboxylic acid from
Scheme 3.1 did not yield the desired product. Using tert-butyl ester 3.030 and slightly different
conditions instead resulted in the desired reduced product 3.031.10 This ester was created by treating
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commercially available 3,5-dimethoxybenzoic acid with thionyl chloride to yield the acid chloride
followed by conversion to the ester.11
Scheme 3.7 – Birch Alkylation with tButyl Ester 3.030

Reagents and conditions: (a) i SOCl2, DCM ii KOtBu, tBuOH (86%); (b) K°, NH3, tBuOH, MeI, -78 °C
(88%); (c) LiAlH4 (89%); (d) NaH, BnBr (95%); (e) HCl (96%); (f) DMAP, DCM, Ac2O, iPr2Net (45%)

From the new Birch product 3.031, the synthesis followed the previously established Scheme 3.2 route
to achieve triketone 3.034, which was then used in both synthetic routes (Scheme 3.8) to yield
compounds 3.019 and 3.038.
3.2.3 Deprotection
With our much sought-after quaternary carbon analog in hand we began deprotection efforts. Again,
standard dehydrogenation conditions proved ineffective for us and so we turned to the FeCl3 procedure
used to obtain 3.035 and 3.039. This was successful and led to the stable primary alcohol 3.039 (Scheme
3.8).
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3.2.4 Analog Synthesis
Having obtained the unprotected alcohol of our advanced intermediate 3.039, we then began testing
conditions to create analogs through ether formation. We started first with NaH as the base and methyl
iodide as the alkyl halide. When this reaction did not produce the ether, we attempted multiple other
bases including triethylamine (TEA), K2CO3, KH, and n-butyllithium.
Scheme 3.8 – Synthesis and Deprotection of Modified Quaternary Carbon Series

Reagents and conditions: (a) 2.009, MeOH, AcOH (64%); (b) 2.018, MeOH, AcOH (70%); (c) 3methoxypropan-1-amine, NaOtBu, Pd(OAc)2, DPPF, 100 °C (81%); (d) NaOH, H2O2, EtOH, 100 °C (58%)
(e) ) FeCl3, DCM; (f) ) FeCl3, DCM (33%)
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We also tried conditions with alternate alkyl halides including ethyl iodide. With no success despite our
multiple attempts we decided to prioritize the formation of analogs over the elegance of the synthesis.
We resigned ourselves to the creation of each analog via a less streamlined synthesis. Essentially, we
began to make each from the original ether creation step (the step when we protected our alcohol).
From this point each analog would be taken step-wise through the synthesis to create the final desired
product.
3.2.5 Modified Birch Alkylation
This revelation, that we would need to use a less convergent synthesis than anticipated, forced us to
relook at the Birch alkylation. Our need to synthesize a great quantity of the Birch reduced intermediate
made the clumsy tert-butyl ester Birch alkylation less ideal. This previous reaction contained difficult
steps (from a health aspect, removing thionyl chloride under reduced pressure) and had begun to yield
reduced amounts of product. We did an extensive study of various Birch conditions and thus informed;
we began to systematically test several conditions of the Birch alkylation on a carboxylic acid instead. We
attempted using different reducing metals. Lithium seemed to be the preferred reducing metal for Birch
alkylations in the literature, but we tried sodium and potassium as well. We undertook extreme
measures to ensure the entire reaction remained under argon and pre-dried the liquid ammonia and
cosolvent. With these conditions and the use of lithium and 3,5-dimethoxybenzoic acid (Scheme 3.9), we
achieved the desired product 3.040, which could then be reduced using previous methods to yield 3.032.
Scheme 3.9 – Birch Alkylation Revisited

Reagents and conditions: (a) Li°, NH3, MeI, 78 °C (96%) (b) LiAlH4 (64%)
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Now with a straightforward synthesis for 3.032 we began synthesizing each analog from different ether
versions of 3.032 as shown in Scheme 3.10. Each ether then followed the previously outlined synthetic
scheme to yield the final compounds 3.046 A-G. We chose to focus on synthesizing the carboxamide top
portion of these compounds.
Scheme 3.10 – Ether Analog Synthesis

Reagents and conditions: (a) NaH, RX; (b) HCl (aq); (c) DMAP, DCM, Ac2O, iPr2NEt; (d) 2.018, MeOH,
AcOH; (e) 3-methoxypropan-1-amine, NaOtBu, Pd(OAc)2, DPPF, 100 °C; (f) NaOH, H2O2, EtOH, 100 °C

3.3: Assay Overview
Analogs were tested in two types of assays against leishmaniasis, an axenic amastigote assay (aa) and an
infected macrophage assay (im). The axenic amastigote assay (aa assay) used an engineered cell line,
which represented the mammalian-infective stage of the parasite. This cell line allowed a high
throughput screening to be conducted in search of active compounds. The aa assay treated the
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amastigote form of the parasite directly with test compounds. After a fixed incubation time, the number
of surviving parasites in the assay was visualized and counted.
The other assay used was as an infected macrophage assay (im assay) which provided a more relevant
determination of IC50 values. In the im assay, macrophages were infected with amastigotes, then treated
with the compound of interest and incubated for a fixed time. The surviving parasite population was
then visualized and counted. This assay required the test compounds to pass through the membranes of
both the macrophage as well as the amastigote; mimicking some of the challenges that possible
treatments would be expected to encounter. Compounds active in the aa assay were later run in the
more relevant im assay.
3.3.1 Assay Results

Figure 3.3 – Analog Structure Summary
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Figure 3.3 shows a summary of all the compounds we created for evaluation of anti-leishmanial activity
and Table 3.1 shows the results of each analog in the assays conducted by the Kyle group. As previously
discussed, the replacement of geminal methyls with hydrogens on 2.002 showed a complete loss of
activity. The original quinazoline top portion analog 2.003, which was proposed to eliminate synthetic
steps was active; although less active when compared with its analogous counterpart 2.001.
Table 3.1 – Summary of Biological data for Synthesized Analogs
Ic50 (µg/mL)
Compound
SNX 2112
2.001
2.002
2.003
2.016
2.021
3.007
3.011
3.016
3.017
3.019
3.038
3.039
3.046 A
3.046 B
3.046 C
3.046 D
3.046 E
3.046 F
3.046 G
Miltefosine

Infected
Macrophage
Assay (IM)
0.61
0.88
10
2.42
0.87
4.04
3.54
10
1.77
10
10
0.61
>10
9.67
0.6
1.77
1.78
2.37
>10
>10
1.27

Axenic Amastigote
Assay (AA)
0.42
0.65
>10
4.55
4.15
0.48
2.23
>10
6.44
>10
7.76
8.29
4.18
7.97
9.54
2.8
6.33
>10
>10
>10
2.92

The benzyl ether quinazoline analog 3.007 showed only a slight decrease in activity compared to 2.003,
which suggested that the hydrophobic pocket could accommodate larger functionality than the dimethyl groups. Strangely, the quinazoline analogs showed no discernable link to the corresponding
analogs with the carboxamide top portion. While a change from the benzyl ether to the methyl ether in
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the quinazoline (3.007 to 3.011) produced a complete loss in activity, the same transformation with the
carboxamide top segment (3.017 to 3.016) showed the reverse effect. It is not clear why this might
occur; one suggestion is that the quinazoline analogs are binding in a different orientation or to a
different site in the target than the carboxamide analogs. Since the quinazoline analogs did not trend
with the corresponding carboxamide compound’s activities, we abandoned their use for the remaining
analogs. In addition, there were no obvious trends or rationale for the observed SAR. Activity did not
seem to increase or decrease with the elongation of the ether carbon chain.
The benzyl ether 3.038 was significantly more active than the methyl ether 3.046A, and the ethyl ether
3.046B seemed to regain activity. One possible explanation for the scattering of activities could be the
difficulty in crossing both membranes (the macrophage and parasite) in the infected macrophage assay.
This challenge could present unforeseen variables that may prefer very specific chemistry. Despite this,
we did achieve several compounds that showed increased activity over the current therapy miltefosine.
These include the cyclopropyl analog 2.016 as well as the ethyl ether 3.046B and the benzyl ether 3.038
analogs.
3.3.2 Other and Future Assays
In addition to studying our compounds in the im and aa assays, we chose several of our most active
compounds to be submitted to a human Hsp90 assay performed by Gabriela Chiosis’ laboratory at
Memorial Sloan Kettering. The only compounds that showed potent activity were compound
2.001(shown in Figure 3.4 as 1) and 2.003 (shown in Figure 3.4 as 9) and the desmethylated analog
2.002 (shown as 10 in Figure 3.4). This data is noteworthy since 2.002 showed a complete loss of activity
in the Leishmania assay. None of the other synthesized compounds showed significant Hsp90 inhibitory
activity. This observation that the Hsp90 activity of our compounds does not seem to parallel the antileishmaniasis activity, could suggest the possibility that these compounds might either be acting through
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another mechanism of inhibition or they are showing selectivity to protozoan Hsp90 orthologs over
human.

Figure 3.4 – Human Hsp90 Fluorescence Assay
Currently there are no assays available that use L. donovani Hsp90. However, we submitted some of our
most active compounds to Wes Van Voorhis at the University of Washington to be used in a study to help
elucidate the crystal structure of N. fowleri Hsp90. He found that when N. fowleri Hsp90 was treated
with our compounds there was an increase in the melting temperature of the complex. This would
suggest that the analogs were binding to the N. fowleri Hsp90 protein thereby stabilizing it and
increasing the melting temperature. If this is the case, this may imply that these compounds are
selectively binding to protozoan Hsp90 while not binding to the human ortholog. Such a discovery would
increase the viability of the use of these compounds in the treatment of leishmaniasis.
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3.4 Leishmaniasis Conclusions
Overall, we have made several analogs of our original target. These compounds were derivatives of the
compound SNX 2112, a compound that was used in clinical trials and showed good pharmacological
properties. Several of our analogs showed greater activity than the current standard treatment
miletofosine in an im leishmaniasis assay. In addition, we have seen some evidence that these
compounds may be exhibiting anti-leishmaniasis activity by inhibiting a protozoan specific ortholog of
Hsp90. The future direction of this project will be determined by results obtained from ongoing assays.

Figure 3.5 – Melting Temperature of N. fowleri Hsp90 protein
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3.6 Experimental Section
General Synthetic Procedures:

3,5-Dimethoxycyclohexa-2,5-diene-1-carboxylic acid : To a solution of 3,4,5-trimethoxybenzoic acid
(17.1 g, 81 mmol) in 40 ml methanol was condensed 400 mL of liquid ammonia at -78 °C. Sodium (10.8 g,
470 mmol) was added by small pieces until the solution remained dark blue. Ammonium chloride (40.5
g, 757 mmol) was added and the ammonia was allowed to evaporate overnight at room temperature.
The solid residue was dissolved in ice water and then acidified using 6N aqueous HCl and a precipitate
was formed. The solution was extracted with CH2Cl2, and the aqueous layer was reacidifed and
reextracted until addition of acid no longer produced precipitate. The combined organic layers and were
dried with Na2SO4 and filtered. The solution was concentrated under reduced pressure to yield 3.002 as
a cream-colored crystalline solid (14.8 g, 99 %). 1H NMR (400 MHz, CDCl3) δ 11.01 (br. s, 1H), 4.75 (d,
J=3.51 Hz, 1H), 3.95 (tt, J=3.56, 6.98 Hz, 1H), 3.59 (s, 6H), 2.70 - 2.86 (m, 2H) 13C NMR (400 MHz, CDCl3) δ
180.2, 154.0, 89.0, 54.4, 42.3, 31.0.

(3,5-Dimethoxycyclohexa-2,5-dien-1-yl)methanol : To a solution of lithium aluminum hydride (6.2 g, 164
mmol) in 50 mL of dry THF under argon was added a slurry of 3.002 (14.8 g, 80 mmol) in 130 mL of
diethyl ether. The mixture was stirred under argon at room temperature for one hour then cooled to 0
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°C. 6.2 mL of water was added, then 6.2 mL of 15% aqueous NaOH was added followed by an additional
20 mL of water and the solution was stirred for 15 minutes. MgSO4 was added and the sample was
filtered and flushed with ethyl acetate followed by the extraction of the aqueous layer with Ethyl acetate
(3 x 200mL). The product was concentrated to yield 3.003 as a light-yellow oil (11.2 g, 82 %). The product
was used crude in the next step.

(((3,5-Dimethoxycyclohexa-2,5-dien-1-yl)methoxy)methyl)benzene : To 60% suspension of NaH in
mineral oil (3.7 g, 92 mmol) in 100mL of dry THF was added 3.003 (11.2 g, 65.9 mmol) in 100 mL of dry
THF dropwise under argon. A catalytic amount of tetrabutylammonium iodide and benzyl bromide (9.3
mL, 78 mmol) was added to the solution. The reaction was stirred at room temperature overnight. 45 mL
of methanol was added to the solution and stirred for 30 minutes. The mixture was partitioned between
ethyl acetate (200 mL) and water (200 mL). The aqueous phase was then extracted twice with ethyl
acetate (200 mL). The combined organic phase was dried over Na2SO4, filtered and concentrated under
reduced pressure to yield a yellow oil, which was purified by column chromatography (silica gel, eluent:
hexanes/ ethyl acetate 50:1) to yield 3.004 as a clear oil (12.9 g, 75 %). 1H NMR (400 MHz, CDCl3) δ 7.27 7.48 (m, 5H), 4.76 (d, J=1.56 Hz, 2H), 4.60 (s, 2H), 3.60 (s, 6H), 3.39 - 3.43 (m, 2H), 3.31 - 3.38 (m, 1H),
2.87 (d, J= 6.25 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 152.9, 138.7, 128.4, 127.6, 127.6, 92.8, 76.6, 73.1,
54.1, 36.9, 31.5
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5-((B)methyl)cyclohexane-1,3-dione : To a solution of 3.004 (9.7 g, 37 mmol) in 350 mL THF was added
10% aqueous HCl (34 mL, 112 mmol) and the solution was stirred at room temperature for four days.
The solvent was removed under reduced pressure and product was taken up in 200 mL CH2Cl2, dried
over Na2SO4, filtered and concentrated. The crude product was purified by column chromatography
(silica gel, eluent: hexanes/ ethyl acetate 2:1) to yield 3.005 (7.0 g, 81 %). 1H NMR (400 MHz,
METHANOL-d4) δ 7.16-7.40 (m, 5H), 5.45 (s, 1H), 4.47 (s, 2H), 3.32-3.54 (m, 2H), 2.01-2.77 (m, 5H).

13

C

NMR (101 MHz, METHANOL-d4) δ 200.9, 138.2, 128.0, 127.3, 72.7, 72.5, 53.1, 39.1, 34.1, 31.5

2-Acetyl-5-((benzyloxy)methyl)cyclohexane-1,3-dione : To 3.005 (0.20 g, 0.89 mmol) in 50 mL CH2Cl2
was added DMAP (0.03 g, 0.3 mmol) and Hunig's base (0.16 mL, 0.89 mmol). A solution of acetyl
chloride (0.06 mL, 0.9 mmol) and 7.5 mL CH2Cl2 was added dropwise and the mixture was heated to
reflux for 2 hours. The mixture was concentrated then partitioned between 3 mL of 1 M HCl and 7 mL of
2:1, hexane / ethyl acetate. The organic layer was washed with brine, dried over MgSO4, filtered and
concentrated to yield 3.006 (0.21 g, 84 %). 1H NMR (CDCl3, 400 MHz): δ 7.2-7.4 (m, 5H), 4.49 (s, 2H), 3.40
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(dd, 2H, J=5.1, 11.7 Hz), 2.7-2.8 (m, 1H), 2.57 (s, 3H), 2.5-2.6 (m, 1H), 2.3-2.4 (m, 2H). 13C NMR (CDCl3,
101 MHz): δ 202.7, 198.0, 194.7, 137.9, 128.4, 127.7, 127.5, 113.1, 73.2, 72.5, 41.7, 36.3, 31.8, 28.7.

1-(4-Aminoquinazolin-7-yl)-6-((benzyloxy)methyl)-3-methyl-1,5,6,7-tetrahydro-4H-indazol-4-one :
Using conditions identical to those described above for compound 2.010, 3.006 was converted to 3.007
as a light yellow solid (93%).

13

C NMR (CDCl3, 101 MHz): δ 193.1, 160.9, 156.2, 150.8, 150.5, 149.8,

142.4, 137.8, 128.4, 127.6, 123.6, 122.1, 120.3, 118.6, 112.9, 73.2, 72.6, 41.5, 37.1, 27.4, 13.4. HRMS
m/z: [M + H]+ calc’d for C24H24N5O2 414.193; Found 414.1946

1,5-Dimethoxy-3-(methoxymethyl)cyclohexa-1,4-diene : Using conditions identical to those described
above for compound 3.004, 3.003 was converted to 3.008 as a yellow oil used directly in the next step
(94%).
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5-(methoxymethyl)cyclohexane-1,3-dione : Using conditions identical to those described above for
compound 3.005. 3.008 was converted to 3.009 (14 %). 1H NMR (CD3OD, 400 MHz): δ 7.2-7.4 (m, 5H),
5.45 (s, 1H), 4.47 (s, 2H), 3.3-3.5 (m, 2H), 2.0-2.8 (m, 5H). 13C NMR (CD3OD, 101 MHz): δ 200.9, 138.2,
128.0, 127.3, 72.7, 72.5, 53.1, 39.1, 34.1, 31.5

2-acetyl-5-(methoxymethyl)cyclohexane-1,3-dione : Using conditions identical to those described above
for compound 3.006. 3.009 was converted to 3.010 as a yellow oil (49.0 %). 13C NMR (CDCl3, 101 MHz) δ
202.8, 198.0, 194.8, 113.0, 75.1, 59.0, 41.6, 36.2, 31.7, 28.7.
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1-(4-Aminoquinazolin-7-yl)-6-(methoxymethyl)-3-methyl-1,5,6,7-tetrahydro-4H-indazol-4-one : Using
conditions identical to those described above for compound 2.010, 3.010 was converted to 3.011 as a
light yellow solid (31.0 %). 1H NMR (DMSO-d6, 500 MHz): δ 8.4-8.4 (m, 1H), 8.37 (d, 1H, J=8.7 Hz), 7.92
(br s, 2H), 7.7-7.8 (m, 2H), 3.35 (d, 2H, J=6.1 Hz), 3.32 (s, 2H), 3.22 (s, 3H), 3.03 (s, 2H), 2.4-2.4 (m, 3H),
2.39 (br d, 1H, J=4.0 Hz). 13C NMR (DMSO-d6, 126 MHz): δ 193.0, 162.0, 157.1, 150.8, 150.6, 149.4, 141.9,
125.9, 121.1, 120.3, 118.1, 113.6, 75.2, 58.7, 41.4, 36.5, 26.6, 13.6. HRMS m/z: [M + H]+ calc’d for
C18H20N5O2 338.1617; Found 338.1615.

2-Bromo-4-(6-(methoxymethyl)-3-methyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzonitrile : Using
conditions identical to those described above for compound 2.019, 3.010 was converted to 3.012 as a
yellow-white solid (27.1 %). 1H NMR (CDCl3, 400 MHz): δ 7.92 (d, 1H, J=1.8 Hz), 7.73 (d, 1H, J=8.4 Hz),
7.55 (dd, 1H, J=1.9, 8.4 Hz), 3.3-3.4 (m, 2H), 3.32 (s, 3H), 3.0-3.1 (m, 1H), 2.9-3.0 (m, 1H), 2.4-2.6 (m, 8H).
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C NMR (CDCl3, 101 MHz): δ 192.7, 151.3, 149.6, 142.5, 134.9, 127.2, 126.3, 121.3, 119.1, 116.5, 114.2,

75.0, 59.0, 41.2, 36.9, 27.0, 13.3.

4-(6-(Methoxymethyl)-3-methyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((3methoxypropyl)amino)benzonitrile : Using conditions identical to those described above for compound
2.020, 3.012 was converted to 3.014 as a yellow-white solid (58.1%).

4-(6-(Methoxymethyl)-3-methyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((3methoxypropyl)amino)benzamide : Using conditions identical to those described above for compound
2.021, 3.014 was converted to 3.016 as a white solid (82 %). 1H NMR (CDCl3, 400 MHz): δ 8.0-8.1 (m, 1H),
7.44 (d, 1H, J=8.4 Hz), 6.77 (d, 1H, J=1.6 Hz), 6.59 (dd, 1H, J=1.8, 8.4 Hz), 5.90 (br s, 2H), 3.47 (s, 2H), 3.3-
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3.4 (m, 2H), 3.30 (d, 6H, J=0.8 Hz), 3.3-3.3 (m, 1H), 3.0-3.1 (m, 1H), 2.8-2.9 (m, 1H), 2.5-2.5 (m, 5H), 2.32.4 (m, 1H), 1.9-1.9 (m, 1H), 1.87 (br s, 1H). 13C NMR (CDCl3, 101 MHz): δ 193.0, 151.1, 150.0, 149.3,
142.6, 129.5, 118.0, 112.2, 108.9, 106.2, 75.3, 70.2, 59.0, 58.7, 41.4, 40.1, 36.9, 29.1, 26.8, 13.4. HRMS
m/z: [M + H]+ calc’d for C21H28N4O4 401.2189; Found 401.2193

4-(6-((Benzyloxy)methyl)-3-methyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-bromobenzonitrile :
Using conditions identical to those described above for compound 2.019, 3.006 was converted to 3.013
as a yellow-white solid (81%). 1H NMR (CDCl3, 400 MHz): δ 7.93 (s, 1H), 7.74 (d, 1H, J=8.4 Hz), 7.56 (br d,
1H, J=8.4 Hz), 7.3-7.4 (m, 5H), 4.5-4.6 (m, 2H), 3.4-3.6 (m, 2H), 2.9-3.1 (m, 2H), 2.5-2.6 (m, 5H). 13C NMR
(CDCl3, 101 MHz): δ 192.7, 151.4, 149.6, 142.6, 137.8, 134.9, 128.5, 127.9, 127.6, 127.1, 126.3, 121.3,
116.5, 114.3, 73.2, 72.4, 41.3, 37.0, 27.1, 13.4

4-(6-((Benzyloxy)methyl)-3-methyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((3methoxypropyl)amino)benzonitrile : Using conditions identical to those described above for compound
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2.020, 3.013 was converted to 3.015 as a yellow-white solid (24.0%). 1H NMR (CDCl3, 500 MHz): δ 7.46
(d, 1H, J=8.3 Hz), 7.2-7.4 (m, 5H), 6.83 (d, 1H, J=1.5 Hz), 6.70 (dd, 1H, J=1.7, 8.3 Hz), 4.5-4.6 (m, 2H), 3.53.6 (m, 3H), 3.48 (br d, 1H, J=6.3 Hz), 3.3-3.4 (m, 5H), 3.0-3.1 (m, 1H), 2.91 (dd, 1H, J=9.6, 16.6 Hz), 1.95
(quin, 2H, J=5.9 Hz). 13C NMR (CDCl3, 126 MHz): δ 192.9, 151.4, 150.4, 149.3, 143.4, 137.8, 133.7, 128.4,
127.8, 127.6, 118.4, 117.2, 110.5, 105.1, 94.9, 73.2, 72.6, 71.2, 58.8, 42.0, 41.5, 37.0, 28.5, 27.0, 13.4.

4-(6-((Benzyloxy)methyl)-3-methyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((3methoxypropyl)amino)benzamide : Using conditions identical to those described above for compound
2.021, 3.015 was converted to 3.017 as a white solid (82.2 %). 1H NMR (CDCl3, 500 MHz): δ 7.46 (d, 1H,
J=8.8 Hz), 7.3-7.3 (m, 2H), 7.2-7.3 (m, 3H), 6.80 (d, 1H, J=2.0 Hz), 6.61 (dd, 1H, J=2.2, 8.6 Hz), 5.9-6.2 (m,
2H), 4.5-4.5 (m, 2H), 3.4-3.5 (m, 4H), 3.31 (s, 3H), 3.3-3.3 (m, 2H), 2.9-3.1 (m, 2H), 2.5-2.6 (m, 2H), 2.51
(s, 3H), 2.4-2.5 (m, 1H), 1.91 (quin, 2H, J=6.4 Hz). 13C NMR (CDCl3, 126 MHz): δ 193.1, 171.4, 151.0,
150.0, 149.3, 142.6, 137.9, 129.6, 128.4, 127.8, 127.5, 118.0, 112.3, 109.0, 106.2, 73.2, 72.8, 70.2, 58.7,
41.6, 40.2, 37.0, 29.1, 26.9, 13.4. HRMS m/z: [M + H]+ calc’d for C27H33N4O4 477.2502; Found 477.2514.

2-((Benzyloxy)methyl)oxirane : In a round-bottomed flask was added oxiran-2-ylmethanol (1.0 g, 10
mmol), benzyl bromide (1.6 mL, 14 mmol), NaH (60% suspension in mineral oil) (0.7 g, 30 mmol) in 50
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mL of dry DMSO. A catalytic amount of n-butyl ammonium iodide was added to the solution and it was
heated to 65 °C for five hours. The solution was cooled to rt washed with H2O and extracted with diethyl
ether (3 x 100 mL). The organic was washed with H2O and dried over MgSO4. The crude product was
purified by column chromatography (silica gel, eluent: hexanes/ ethyl acetate 10:1) to yield 3.025 (1.3 g,
55 %). 1H NMR (CDCl3, 500 MHz): δ 7.37 (d, 5H, J=4.7 Hz), 4.61 (d, 2H, J=15.9 Hz), 3.79 (dd, 1H, J=3.0,
11.5 Hz), 3.46 (dd, 1H, J=5.9, 11.4 Hz), 3.21 (td, 1H, J=2.9, 4.1 Hz), 2.81 (dd, 1H, J=4.3, 4.9 Hz), 2.63 (dd,
1H, J=2.8, 5.1 Hz).

1-(Benzyloxy)propan-2-ol
In a round-bottomed flask was added LiAlH4 (2.4 g, 62 mmol) in 20 mL Ether. 3.025 (10.24 g, 62.4 mmol)
was dissolved in 5 mL of ether and added. The mixture was refluxed at 37 °C for 4 hours.
The solution was cooled to rt and 1N aq NaOH was added dropwise to the mixture until the solution
went from a grey suspension to clear with white solids. Precipitated metal salts were removed by
filtration.
The solution was washed with water, dried over MgSO4, filtered and concentrated under reduced
pressure to yield 3.026 (9.9 g, 95 %) as a clear oil. 1H NMR (CDCl3, 400 MHz): δ 7.33 (s, 5H), 4.55 (s, 2H),
3.99 (ddd, 1H, J=3.1, 6.2, 8.2 Hz), 3.46 (dd, 1H, J=3.1, 9.4 Hz), 3.27 (dd, 1H, J=8.2, 9.4 Hz), 2.0-2.2 (m, 1H),
1.14 (d, 3H, J=6.2 Hz).

1-(Benzyloxy)propan-2-one : In a round-bottomed flask was added 3.026 (9.9 g, 60 mmol) in 25 mL
DCM. PCC (16.2 g, 75 mmol) was added along with Celite and the reaction was stirred at RT. After 12
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hours the reaction was filtered and concentrated. The crude product was purified by column
chromatography (silica gel, eluent: DCM) to yield 3.023 (7.6 g, 78 %) as a colorless oil. 1H NMR (CDCl3,
500 MHz): δ 7.3-7.4 (m, 5H), 4.6-4.6 (m, 2H), 4.07 (s, 2H), 2.18 (s, 3H).

Ethyl (E)-4-(benzyloxy)-3-methylbut-2-enoate : In a round-bottomed flask was added NaH (60%
suspension in mineral oil) (3.7 g, 92 mmol) in 10 mL dry THF at 0 °C to give a white suspension. Triethyl
phosphonoacetate (10.2 mL, 50.7 mmol) was added and the solution was stirred for 0.5 hr at 0 °C. 3.023
(7.6 g, 46 mmol) was diluted in 5 mL dry THF and added to the solution. The reaction was stirred at rt
overnight then quenched with H2O and extracted with DCM (3 x 50 mL). The combined organic layers
were washed with brine, dried over MgSO4,, filtered and concentrated under reduced pressure. The
crude product was purified by column chromatography (silica gel, eluent: hexanes/ ethyl acetate 9:1) to
yield 3.027 (3.5 g, 32 %). 1H NMR (CDCl3, 400 MHz): δ 7.2-7.4 (m, 5H), 5.7-5.8 (m, 1H), 4.66 (s, 2H), 4.51
(s, 2H), 4.12 (q, 2H, J=7.2 Hz), 2.01 (s, 3H), 1.26 (br t, 3H, J=7.2 Hz).

(E)-4-(Benzyloxy)-N-methoxy-N,3-dimethylbut-2-enamide : In a round-bottomed flask was added 3.027
(1.3 g, 5.5 mmol) and N,O-dimethylhydroxylamine hydrochloride (1.3 g, 13 mmol) in 50 mL dry THF at 0
°C under argon. Isopropylmagnesium chloride (14 mL, 28 mmol) was added dropwise over thirty minutes
at 0 °C under argon. The solution was stirred for 1 hour at 0 °C under argon then quenched with
saturated NH4Cl. The solution was extracted with ether (3 x 30mL) and the combined organic layer was
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washed with brine, dried over MgSO4, filtered and evaporated under reduced pressure to yield 3.028
(1.3 g, 96 %). The product was used directly in the next step.

(E)-5-(Benzyloxy)-4-methylpent-3-en-2-one : In a round-bottomed flask was added 3.028 in 100 mL of
dry THF at 0 °C. methylmagnesium bromide (2.6 mL, 7.7 mmol) was added slowly to the solution. The
reaction was stirred at 0 °C for 1 hour under argon then quenched with saturated NH4Cl. The reaction
was extracted with ether (2 x 15 mL), washed with brine, dried over MgSO4, filtered and evaporated
under reduced pressure. The crude product was purified by column chromatography (silica gel, eluent:
hexanes/ ethyl acetate 20:1) to yield 3.029 (0.6 g, 70 %). 1H NMR (CDCl3, 400 MHz): δ 7.3-7.4 (m, 5H),
6.37 (br s, 1H), 4.4-4.6 (m, 3H), 3.96 (s, 2H), 2.19 (s, 3H), 2.03 (s, 3H)

tert-Butyl 3,5-dimethoxybenzoate : In a dry round-bottomed flask was added 3,5-dimethoxybenzoic acid
(8.3 g, 45 mmol) under argon in 165 mL DCM and SOCl2 (6.6 mL, 91 mmol) was added. The solution was
refluxed under argon overnight. The solvent was removed under reduced pressure and the product was
immediately used in the next step. In a round-bottomed flask was added 100 mL of t-butanol under
argon and potassium t-butoxide (9.2 g, 82 mmol) and the reaction was stirred at rt for 15 minutes. 3,5dimethoxybenzoyl chloride (11.0 g, 54.9 mmol) (from the above step) was added as a solution in 10 mL
THF. The reaction was then heated to reflux under nitrogen overnight. The solution was washed with
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saturated NaCl (3 x 250 mL), washed with saturated sodium bicarbonate, dried over MgSO4, filtered and
concentrated under reduced pressure to yield 3.030 (11.9 g, 91 %) as a white semisolid which was used
without purification in the next step.

tert-Butyl 3,5-dimethoxy-1-methylcyclohexa-2,5-diene-1-carboxylate : To a 100 mL three-necked round
bottom flask was added 3.030 (5 g, 20 mmol) and t-butanol (2.4 mL, 25 mmol) in in 10 mL of dry THF.
Approximately 20 mL of sodium dried liquid ammonia (61.3 mL, 2830 mmol) was added to the flask at
-78 °C. Sodium (0.145 g, 6.30 mmol) was added in small pieces until it dissolved and methyl iodide (7.0
mL, 100 mmol) (which was diluted in 10 mL THF and filtered through alumina first) was added. The
reaction was stirred at -78 °C for an additional 2 hours and the ammonia was evaporated overnight. The
reaction was concentrated under reduced pressure and then extracted between water and ether several
times. The organic layers were concentrated under reduced pressure to yield 3.038 (4.7 g, 88%) as a
white solid used without further purification in the next step.

(3,5-Dimethoxy-1-methylcyclohexa-2,5-dien-1-yl)methanol : In a round-bottomed flask was added
LiAlH4 (1.1 g, 28 mmol) in 25 mL THF under argon and stirred. 3.031 (3.6 g, 14 mmol) as a slurry in diethyl
ether (22.4 mL) was added slowly at 0 °C then warmed to rt and stirred under argon for one hour. The
solution was cooled to 0 °C and 1.4 mL of water was slowly added. After bubbling ceased 1.4 mL of 15%
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aqueous NaOH was added, followed by an additional 6 mL of water. The solution was allowed to stir at rt
for 15 minutes. MgSO4 was added and the sample was filtered and flushed with THF. The solution was
then evaporated under reduced pressure to yield 3.032 (89.0 %) as a very light-yellow oil which was used
without purification in the next step.

(((3,5-Dimethoxy-1-methylcyclohexa-2,5-dien-1-yl)methoxy)methyl)benzene : Using conditions
identical to those described above for compound 3.004, 3.032 was converted to 3.033 (95 %). 1H NMR
(CDCl3, 400 MHz): δ 7.3-7.4 (m, 5H), 4.54 (d, 4H, J=6.0 Hz), 3.55 (s, 6H), 3.2-3.2 (m, 2H), 2.7-2.8 (m, 2H),
1.16 (s, 3H). 13C NMR (CDCl3, 101 MHz): δ 151.6, 138.9, 128.2, 127.4, 99.2, 80.5, 73.2, 54.1, 39.6, 31.4,
27.5.

5-((Benzyloxy)methyl)-5-methylcyclohexane-1,3-dione : Using conditions identical to those described
above for compound 3.005, 3.033 was converted to 3.020 of a white solid (37.8 %). 1H NMR (CDCl3, 400
MHz): δ 7.1-7.4 (m, 5H), 4.36 (s, 2H), 3.22 (s, 2H), 3.20 (t, 1H, J=2.0 Hz), 3.14 (s, 1H), 2.6-2.6 (m, 2H), 2.41
(d, 2H, J=14.8 Hz), 0.99 (s, 3H). 13C NMR (CDCl3, 101 MHz): δ 203.1, 137.1, 128.4, 127.8, 127.7, 78.5, 73.5,
56.0, 51.0, 36.3, 24.3.
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2-Acetyl-5-((benzyloxy)methyl)-5-methylcyclohexane-1,3-dione : Using conditions identical to those
described above for compound 3.006, 3.020 was converted to yield 3.034 (45.4 %). 1H NMR (CDCl3, 400
MHz): δ 7.2-7.4 (m, 5H), 4.48 (s, 2H), 3.21 (s, 2H), 2.6-2.9 (m, 2H), 2.56 (s, 3H), 2.2-2.4 (m, 2H), 1.02 (s,
3H).

13

C NMR (CDCl3, 101 MHz): δ 201.9, 198.1, 195.0, 137.9, 128.4, 127.7, 127.4, 112.5, 73.3, 47.9,

42.2, 34.9, 28.4, 23.2.

1-(4-Aminoquinazolin-7-yl)-6-((benzyloxy)methyl)-3,6-dimethyl-1,5,6,7-tetrahydro-4H-indazol-4-one :
Using conditions identical to those described above for compound 2.010, 3.034 was converted to 3.019
as a light yellow solid (63.6 %). 1H NMR (500 MHz, CDCl3) δ 8.64 (s, 1H), 7.85-7.93 (m, 3H), 7.75-7.83 (m,
1H), 7.21-7.34 (m, 6H), 6.13 (br s, 2H), 4.42-4.56 (m, 2H), 4.12 (q, J=7.15 Hz, 1H), 3.41 (d, J=16.75 Hz, 1H),
3.28 (q, J=9.11 Hz, 2H), 2.74-2.84 (m, 2H), 2.56 (s, 3H), 2.29-2.35 (m, 1H), 2.12 (s, 1H), 1.04-1.09 (m, 3H).
13

C NMR (CDCl3, 126 MHz): δ 193.0, 160.9, 161.0, 155.8, 149.3, 142.6, 137.9, 128.4, 127.6, 127.4, 123.5,

122.3, 120.2, 73.2, 47.9, 40.1, 36.1, 32.8, 30.4, 23.4, 13.4. HRMS m/z: [M + H]+ calc’d for C25H26N5O2
428.2087; Found 428.2104.
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4-(6-((Benzyloxy)methyl)-3,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-bromobenzonitrile:
Using conditions identical to those described above for compound 2.019, 3.034 was converted to 3.036
as a dark orange solid (69.7 %). 1H NMR (DMSO-d6, 400 MHz): δ 8.1-8.1 (m, 2H), 7.77 (dd, 1H, J=2.0, 8.6
Hz), 7.2-7.3 (m, 5H), 4.41 (dd, 2H, J=5.5, 12.5 Hz), 3.19 (s, 1H), 2.88 (d, 1H, J=17.2 Hz), 2.53 (d, 1H, J=16.4
Hz), 2.36 (s, 3H), 2.27 (d, 1H, J=16.4 Hz), 0.96 (s, 3H). 13C NMR (METHANOL-d4, 101 MHz): δ 193.9, 150.4,
138.1, 135.2, 127.9, 127.2, 127.1, 125.3, 121.9, 117.7, 116.1, 113.9, 76.5, 72.8, 59.9, 39.7, 31.9, 22.5,
13.1, 12.1.

4-(6-((Benzyloxy)methyl)-3,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((3methoxypropyl)amino)benzonitrile : Using conditions identical to those described above for compound
2.02, 3.036 was converted to 3.037 as a yellow oil (81 %). 1H NMR (400 MHz, CDCl3) δ 7.43 (d, J=8.30 Hz,
1H), 7.20-7.35 (m, 6H), 6.83 (d, J=1.46 Hz, 1H), 6.67 (dd, J=1.66, 8.30 Hz, 1H), 5.41-5.57 (m, 1H), 4.424.54 (m, 2H), 3.53 (t, J=5.47 Hz, 2H), 3.19-3.38 (m, 9H), 2.66 (t, J=16.57 Hz, 2H), 2.50 (s, 4H), 2.27 (d,
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J=16.50 Hz, 1H), 1.92 (quin, J=5.88 Hz, 2H), 1.04 (s, 3H). 13C NMR (CDCl3, 101 MHz): δ 192.9, 151.4, 150.2,
148.8, 143.5, 138.0, 133.7, 128.4, 127.7, 127.4, 117.5, 117.2, 110.5, 105.2, 94.8, 73.3, 71.2, 58.8, 47.9,
42.0, 40.0, 32.5, 28.6, 23.4, 13.4

4-(6-((Benzyloxy)methyl)-3,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((3methoxypropyl)amino)benzamide : Using conditions identical to those described above for compound
2.021, 3.037 was converted to 3.038 as a white solid (58.3 %). 1H NMR (METHANOL-d4, 400 MHz): δ 7.68
(d, 1H, J=8.6 Hz), 7.2-7.3 (m, 3H), 7.1-7.2 (m, 2H), 6.81 (d, 1H, J=2.0 Hz), 6.66 (dd, 1H, J=2.1, 8.4 Hz), 4.42
(d, 2H, J=3.9 Hz), 3.46 (t, 2H, J=5.9 Hz), 3.2-3.3 (m, 6H), 3.18 (s, 1H), 2.79 (d, 1H, J=16.8 Hz), 2.59 (d, 1H,
J=16.4 Hz), 2.43 (s, 3H), 2.34 (d, 1H, J=16.4 Hz), 1.99 (s, 1H), 1.86 (quin, 2H, J=6.3 Hz), 1.05 (s, 3H). 13C
NMR (METHANOL-d4, 126 MHz): δ 194.2, 172.4, 149.9, 149.4, 141.9, 138.2, 130.0, 127.9, 127.2, 127.1,
116.6, 113.4, 108.9, 105.9, 76.6, 72.8, 69.9, 73.0, 57.5, 41.1, 39.6, 39.5, 31.9, 28.7, 22.6, 19.5, 13.1, 11.9.
HRMS m/z: [M + H]+ calc’d for C28H35N4O4 491.2658; Found 491.2661.

65

4-(6-(Hydroxymethyl)-3,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((3methoxypropyl)amino)benzamide
To 2 mL of distilled DCM under argon was added 3.038 (0.12 g, 0.27 mmol). FeCl3 (0.26 g, 1.6 mmol) was
added and the solution was stirred at rt for 72 hours. The reaction was quenched with 1ml H2O and
washed with 10 mL brine. The solution was extracted with DCM and ethyl acetate in a 1:1 ratio (3 x 10
mL). The organic layer was dried on Na2SO4, filtered and concentrated under reduced pressure to yield
3.039 (0.03 g, 30 %). 1H NMR (METHANOL-d4, 500 MHz): δ 7.70 (d, 1H, J=8.3 Hz), 6.85 (d, 1H, J=2.0 Hz),
6.69 (dd, 1H, J=2.0, 8.3 Hz), 3.51 (t, 2H, J=6.1 Hz), 3.3-3.4 (m, 2H), 3.33 (s, 3H), 3.3-3.3 (m, 1H), 3.19 (d,
1H, J=17.1 Hz), 2.72 (d, 1H, J=16.6 Hz), 2.60 (d, 1H, J=16.1 Hz), 2.47 (s, 3H), 2.27 (d, 1H, J=16.6 Hz), 1.91
(quin, 2H, J=6.4 Hz), 1.00 (s, 3H). 13C NMR (METHANOL-d4, 126 MHz): δ 194.4, 172.5, 150.8, 149.9, 149.4,
141.9, 130.0, 116.5, 113.4, 108.9, 105.9, 69.9, 68.5, 57.5, 40.5, 39.5, 31.3, 28.8, 21.5, 11.9. HRMS m/z:
[M + H]+ calc’d for C21H29N4O4 401.2181; Found 401.2189.
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3,5-Dimethoxy-1-methylcyclohexa-2,5-diene-1-carboxylic acid
Under argon at -78 °C was added 3,5-dimethoxybenzoic acid (10 g, 50 mmol) in 150 mL of sodium dried
liquid ammonia to create a colorless solution. Lithium (0.9 g, 100 mmol) was added slowly in small
pieces. When the solution remained blue for at least 10 minutes methyl iodide (7.6 mL, 120 mmol) was
added slowly and the solution became clear. The ammonia was allowed to evaporate overnight under a
stream of nitrogen at RT. The residue was portioned between Et2O and H2O, the aqueous layer was
chilled to 0 °C and acidified to pH 3-4 with careful addition of 2N aq HCl. The aqueous layer was
reextracted with EtOAc. The organic phase was washed with water, dried over MgSO4 and concentrated
on the rotavap to yield 3.040 (96.0 %) which was used without further purifications in the next step.

Using conditions identical to those described above for compound 3.004, 3.032 was converted to
3.041A-G as light oils and used without further purification in the next step.
3.041A Yield (92.0%), 3.041B Yield (39.0%), 3.041C Yield (37.3%), 3.041D Yield (90.0%), 3.041E Yield
(94.0 %), 3.041F Yield (97.0 %), 3.041G Yield (92.0 %)
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Using conditions identical to those described above for compound 3.005. 3.041A-G was converted to
3.042A-G
3.042A Yield (99.0 %), 3.042B Yield (91.0 %).
3.042C Yield (49.7 %). 1H NMR (CDCl3, 500 MHz): δ 3.1-3.3 (m, 6H), 2.3-2.6 (m, 4H), 1.3-1.4 (m, 2H), 1.01.1 (m, 3H), 0.77 (t, 3H, J=7.5 Hz). 13C NMR (CDCl3, 126 MHz): δ 203.4, 79.5, 73.3, 56.0, 51.1, 36.4, 24.3,
22.3, 10.4.
3.042D Yield (7.2 %). 1H NMR (CDCl3, 500 MHz): δ 3.4-3.5 (m, 1H), 3.1-3.3 (m, 4H), 2.4-2.5 (m, 4H), 1.02
(s, 3H), 1.0-1.0 (m, 6H). 13C NMR (CDCl3, 126 MHz): δ 203.5, 76.6, 72.8, 56.1, 51.3, 36.1, 24.4, 21.1.
3.042E Yield (17.3 %). 1H NMR (CDCl3, 500 MHz): δ 4.06 (d, 1H, J=7.1 Hz), 3.1-3.2 (m, 1H), 3.1-3.2 (m, 3H),
3.00 (d, 2H, J=6.5 Hz), 2.5-2.5 (m, 2H), 2.39 (br d, 2H, J=14.9 Hz), 1.98 (s, 1H), 1.64 (q, 1H, J=6.6, 13.3 Hz),
1.20 (t, 1H, J=7.2 Hz), 0.99 (s, 3H), 0.73 (d, 5H, J=6.9 Hz). 13C NMR (CDCl3, 126 MHz): δ 203.2, 79.9, 78.6,
56.0, 51.1, 36.4, 28.1, 24.4, 19.1.
3.042F Yield (25.1 %). 1H NMR (CDCl3, 400 MHz): δ 3.0-3.5 (m, 6H), 2.9-4.1 (m, 1H), 2.3-2.6 (m, 4H), 1.92.1 (m, 1H), 1.21 (br s, 1H), 0.98 (br s, 3H).
3.042G Yield (24.4 %). 1H NMR (CDCl3, 400 MHz): δ 3.34 (t, 2H, J=6.2 Hz), 3.29 (s, 3H), 3.20 (s, 2H), 2.50
(t, 4H, J=1.0 Hz), 1.65 (quin, 2H, J=6.2 Hz), 1.00 (s, 3H). 13C NMR (CDCl3, 101 MHz): δ 203.1, 141.4, 79.6,
69.1, 68.4, 58.5, 56.2, 51.1, 36.3, 29.4, 24.4.
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Using conditions identical to those described above for compound 3.006, 3.042A-G was converted to
3.043A-G.
3.043A Yield (69.4 %), 3.043B Yield (18.1 %)
3.043C Yield (99.0 %). 1H NMR (CDCl3, 400 MHz): δ 3.30 (t, 2H, J=6.5 Hz), 3.12 (s, 2H), 2.57 (s, 3H), 2.54
(s, 3H), 2.2-2.4 (m, 2H), 1.49 (d, 2H, J=7.2 Hz), 0.97 (s, 3H), 0.84 (t, 3H, J=7.4 Hz). 13C NMR (CDCl3, 101
MHz): δ 201.8, 198.3, 195.3, 112.5, 73.1, 47.9, 42.2, 34.9, 28.4, 23.1, 22.7, 10.5.
3.043D Yield (62.0 %). 1H NMR (CDCl3, 500 MHz): δ 3.1-3.1 (m, 1H), 3.14 (s, 2H), 3.13 (s, 1H), 2.88 (d, 1H,
J=18.2 Hz), 2.62 (d, 1H, J=16.4 Hz), 2.58 (s, 3H), 2.38 (dd, 1H, J=1.7, 18.2 Hz), 2.24 (dd, 1H, J=1.6, 16.4
Hz), 1.7-1.8 (m, 1H), 1.00 (s, 3H), 0.84 (d, 5H, J=6.8 Hz), 0.8-0.9 (m, 1H). 13C NMR (CDCl3, 126 MHz): δ
201.7, 198.3, 195.2, 112.6, 78.3, 78.2, 48.1, 42.3, 35.0, 28.4, 23.3, 19.2.
3.043E Yield (74.0 %)
3.043F Yield (29.4 %). 1H NMR (400 MHz, CDCl3) δ 3.44-3.63 (m, 4H), 3.34 (s, 3H), 3.23 (s, 2H), 2.61-2.99
(m, 2H), 2.58 (s, 3H), 2.18-2.46 (m, 2H), 1.01 (s, 3H). 13C NMR (CDCl3, 101 MHz): δ 202.0, 198.1, 195.2,
184.5, 112.5, 78.3, 71.9, 70.9, 59.0, 47.8, 42.0, 36.6, 35.0, 28.4, 23.0.
3.043G Yield (64.3 %). 1H NMR (CDCl3, 400 MHz): δ 3.4-3.5 (m, 4H), 3.3-3.3 (m, 3H), 3.14 (s, 2H), 2.5-2.9
(m, 6H), 2.2-2.4 (m, 2H), 1.76 (t, 2H, J=6.3 Hz), 0.99 (s, 3H). 13C NMR (CDCl3, 101 MHz): δ 201.8, 198.2,
195.2, 112.5, 78.0, 69.5, 68.2, 58.6, 47.9, 42.2, 34.9, 29.8, 28.4, 23.2.
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Using conditions identical to those described above for compound 2.019, 3.043A-G was converted to
yield 3.044A-G
3.044A (37.4 %), 3.044B (99.0 %), 3.044C (17.0 %)
3.044D Yield (93.0 %). 1H NMR (CDCl3, 500 MHz): δ 7.8-8.0 (m, 1H), 7.7-7.8 (m, 1H), 7.5-7.6 (m, 1H), 3.53.6 (m, 1H), 3.2-3.3 (m, 3H), 2.6-2.7 (m, 2H), 2.5-2.6 (m, 3H), 2.2-2.3 (m, 1H), 1.24 (br d, 2H, J=8.6 Hz),
1.1-1.2 (m, 6H), 1.0-1.1 (m, 3H) 13C NMR (CDCl3, 126 MHz): δ 193.1, 150.7, 142.5, 136.5, 134.9, 126.3,
127.0, 121.4, 118.3, 116.6, 74.9, 72.3, 47.8, 40.2, 36.1, 32.4, 23.3, 22.0, 13.4
3.044E Yield (88.0 %). 1H NMR (CDCl3, 400 MHz): δ 7.95 (s, 1H), 7.74 (br d, 1H, J=8.4 Hz), 7.57 (br d, 1H,
J=8.3 Hz), 3.4-3.6 (m, 4H), 3.2-3.4 (m, 6H), 2.6-2.8 (m, 2H), 2.50 (s, 3H), 2.25 (br d, 1H, J=16.5 Hz), 1.02 (s,
3H). 13C NMR (CDCl3, 101 MHz): δ 192.9, 151.2, 149.2, 142.6, 134.9, 127.2, 126.3, 121.3, 118.3, 116.5,
114.2, 78.3, 77.7, 47.8, 40.2, 32.5, 28.3, 23.4, 19.2, 13.3.
3.044F Yield (73.6 %). 1H NMR (CDCl3, 400 MHz): δ 7.96 (d, 1H, J=1.8 Hz), 7.74 (d, 1H, J=8.4 Hz), 7.58 (dd,
1H, J=1.9, 8.4 Hz), 5.27 (s, 1H), 3.5-3.6 (m, 2H), 3.5-3.5 (m, 2H), 3.3-3.4 (m, 7H), 2.6-2.7 (m, 2H), 2.51 (s,
3H), 2.26 (d, 1H, J=16.5 Hz), 1.03 (s, 4H). 13C NMR (CDCl3, 101 MHz): δ 192.5, 151.2, 149.1, 142.6, 134.9,
127.3, 126.3, 121.4, 118.2, 116.5, 114.3, 78.0, 71.8, 70.9, 59.0, 53.4, 47.7, 40.2, 32.3, 23.2, 13.3.
3.044G Yield (65.8 %). 1H NMR (CDCl3, 400 MHz): δ 7.95 (d, 1H, J=1.9 Hz), 7.74 (d, 1H, J=8.5 Hz), 7.58 (br
d, 1H, J=2.0 Hz), 5.27 (s, 1H), 3.46 (br d, 2H, J=6.9 Hz), 3.37 (t, 2H, J=6.3 Hz), 3.28 (s, 3H), 3.2-3.2 (m, 2H),
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2.64 (t, 2H, J=17.4 Hz), 2.50 (s, 3H), 2.25 (d, 1H, J=16.5 Hz), 1.78 (t, 2H, J=6.3 Hz), 1.02 (s, 3H). 13C NMR
(CDCl3, 101 MHz): δ 192.9, 151.1, 149.1, 142.7, 134.9, 127.2, 126.3, 121.3, 118.3, 116.5, 114.3, 69.4,
68.3, 58.6, 47.8, 40.2, 32.5, 29.8, 23.3, 13.3.

Using conditions identical to those described above for compound 2.020, 3.044A-G was converted to
yield 3.045A-G.
3.045A Yield (71.3 %)
3.045B Yield (53.3 %)1H NMR (CDCl3, 400 MHz): δ 7.44 (d, 1H, J=8.3 Hz), 6.83 (d, 1H, J=1.5 Hz), 6.69 (dd,
1H, J=1.7, 8.3 Hz), 5.47 (br s, 1H), 5.27 (s, 1H), 3.53 (t, 1H, J=5.4 Hz), 3.44 (dq, 2H, J=2.9, 6.9 Hz), 3.3-3.4
(m, 3H), 3.2-3.2 (m, 3H), 2.6-2.7 (m, 2H), 2.5-2.5 (m, 3H), 2.23 (br d, 1H, J=16.4 Hz), 1.93 (quin, 1H, J=5.9
Hz), 1.1-1.2 (m, 3H), 1.00 (s, 2H).

13

C NMR (CDCl3, 101 MHz): δ 193.2, 151.4, 150.2, 149.0, 143.5, 134.0,

133.4, 117.5, 117.2, 111.3, 106.0, 94.8, 71.2, 66.8, 58.2, 40.0, 28.5, 23.2, 15.0, 13.6, 13.1.
3.045C Yield (49.8 %). 1H NMR (CDCl3, 400 MHz): δ 7.45 (d, 1H, J=8.3 Hz), 6.83 (d, 1H, J=1.0 Hz), 6.69 (dd,
1H, J=1.4, 8.3 Hz), 5.4-5.5 (m, 1H), 5.28 (s, 1H), 4.5-4.7 (m, 1H), 3.54 (t, 2H, J=5.5 Hz), 3.3-3.4 (m, 6H),
3.2-3.3 (m, 3H), 2.6-2.7 (m, 2H), 2.5-2.5 (m, 4H), 2.24 (d, 1H, J=16.5 Hz), 1.94 (quin, 2H, J=5.9 Hz), 1.53
(td, 3H, J=7.0, 14.0 Hz), 1.01 (s, 3H), 0.85 (t, 4H, J=7.4 Hz). 13C NMR (CDCl3, 101 MHz): δ 193.2, 151.4,
150.2, 149.0, 143.5, 133.7, 117.2, 110.5, 105.2, 94.8, 73.1, 71.2, 58.8, 47.9, 42.0, 40.1, 32.4, 28.6, 23.2,
22.7, 13.4, 10.5.
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3.045D Yield (99.0 %). 1H NMR (CDCl3, 400 MHz): δ 7.44 (d, 1H, J=8.3 Hz), 6.82 (d, 1H, J=1.4 Hz), 6.70 (dd,
1H, J=1.7, 8.3 Hz), 5.4-5.5 (m, 1H), 3.53 (t, 2H, J=5.5 Hz), 3.47 (td, 1H, J=6.1, 12.2 Hz), 3.3-3.4 (m, 5H), 3.13.2 (m, 3H), 2.5-2.7 (m, 2H), 2.50 (s, 3H), 2.22 (d, 1H, J=16.5 Hz), 1.9-2.0 (m, 2H), 1.07 (dd, 6H, J=6.1, 13.8
Hz), 0.99 (s, 3H). 13C NMR (CDCl3, 101 MHz): δ 193.4, 171.3, 151.1, 149.9, 149.0, 142.8, 129.7, 129.1,
117.2, 112.0, 109.7, 107.0, 72.8, 71.6, 70.2, 58.0, 48.2, 40.0, 36.3, 29.2, 23.2, 21.9, 13.6.
3.045E Yield (56.3 %). 1H NMR (CDCl3, 400 MHz): δ 7.44 (d, 1H, J=8.3 Hz), 6.82 (d, 1H, J=1.5 Hz), 6.70 (dd,
1H, J=1.7, 8.3 Hz), 5.48 (br s, 1H), 3.54 (t, 2H, J=5.5 Hz), 3.37 (s, 5H), 3.18 (s, 5H), 2.64 (t, 2H, J=17.2 Hz),
2.51 (s, 3H), 2.25 (d, 1H, J=16.5 Hz), 1.9-2.0 (m, 2H), 1.7-1.9 (m, 1H), 1.01 (s, 3H), 0.83 (dd, 6H, J=1.2, 6.7
Hz). 13C NMR (CDCl3, 126 MHz): δ 193.2, 151.4, 150.2, 149.0, 143.5, 133.7, 117.6, 117.2, 110.5, 105.1,
94.8, 78.3, 77.9, 71.2, 58.8, 48.0, 42.0, 40.2, 32.5, 28.6, 28.3, 23.3, 19.2, 13.4.
3.045F Yield (47.8 %).
3.045G Yield (41.0 %).

Using conditions identical to those described above for compound 2.021, 3.045A-G was converted to
3.046A-G
3.046A Yield (77.0 %). 1H NMR (CDCl3, 500 MHz): δ 7.49 (d, 1H, J=8.4 Hz), 6.83 (d, 1H, J=1.5 Hz), 6.64 (dd,
1H, J=1.7, 8.4 Hz), 5.8-6.1 (m, 2H), 3.49 (t, 2H, J=5.9 Hz), 3.44 (dq, 2H, J=2.1, 7.0 Hz), 3.32 (s, 3H), 3.29 (t,
2H, J=6.8 Hz), 3.2-3.3 (m, 3H), 2.65 (dd, 2H, J=11.1, 16.6 Hz), 2.52 (s, 3H), 2.23 (d, 1H, J=16.4 Hz), 1.93
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(quin, 2H, J=6.4 Hz), 1.13 (t, 3H, J=7.0 Hz), 1.01 (s, 3H). 13C NMR (CDCl3, 126 MHz): δ 193.3, 171.3, 150.8,
149.9, 148.9, 142.7, 129.5, 117.2, 112.4, 109.3, 106.6, 70.2, 66.8, 58.7, 47.9, 40.4, 40.0, 32.3, 29.1, 23.2,
15.0, 13.4. HRMS m/z: [M + H]+ calc’d for C22H31N4O4 415.2337; Found 415.2360.
3.046B Yield (15.6 %) as a white solid. 1H NMR (CDCl3, 500 MHz): δ 7.48 (br d, 1H, J=8.3 Hz), 7.26 (s, 1H),
6.81 (s, 1H), 6.61 (br d, 1H, J=7.8 Hz), 6.03 (br s, 2H), 3.48 (t, 2H, J=5.9 Hz), 3.31 (d, 5H, J=6.5 Hz), 3.2-3.2
(m, 1H), 3.2-3.2 (m, 1H), 3.1-3.2 (m, 1H), 2.62 (br dd, 2H, J=7.9, 16.6 Hz), 2.51 (s, 2H), 2.23 (d, 1H, J=16.4
Hz), 1.92 (quin, 2H, J=6.3 Hz), 1.23 (t, 1H, J=7.1 Hz), 1.01 (s, 2H) 13C NMR (CDCl3, 126 MHz): δ 193.1,
171.4, 150.9, 149.9, 148.8, 142.6, 129.5, 117.1, 112.4, 109.2, 106.5, 79.7, 70.2, 59.3, 58.7, 47.8, 40.3,
39.9, 32.2, 29.1, 23.2, 13.4. HRMS m/z: [M + H]+ calc’d for C23H33N4O4 429.2494; Found 429.2519.
3.046C Yield (28.5 %). 1H NMR (CDCl3, 400 MHz): δ 8.05 (br t, 1H, J=5.0 Hz), 7.45 (d, 1H, J=8.4 Hz), 6.77
(d, 1H, J=1.5 Hz), 6.59 (dd, 1H, J=1.7, 8.4 Hz), 5.95 (br s, 1H), 3.46 (s, 2H), 3.29 (s, 3H), 3.1-3.3 (m, 5H),
2.94 (s, 2H), 2.62 (dd, 2H, J=10.0, 16.5 Hz), 2.49 (s, 3H), 2.21 (d, 1H, J=16.5 Hz), 1.89 (quin, 2H, J=6.3 Hz),
1.49 (sext, 2H, J=7.0 Hz), 0.98 (s, 3H), 0.83 (t, 3H, J=7.4 Hz). 13C NMR (CDCl3, 101 MHz): δ 193.3, 171.4,
151.1, 149.8, 148.9, 142.7, 129.5, 117.1, 112.2, 108.9, 106.2, 77.6, 73.1, 70.2, 58.6, 47.9, 42.6, 40.1,
32.3, 29.1, 23.2, 22.7, 13.4, 10.5. HRMS m/z: [M + H]+ calc’d for C24H35N4O4 443.2650; Found 443.2672.
3.046D Yield (99.0 %). 1H NMR (CDCl3, 400 MHz): δ 7.8-8.4 (m, 1H), 7.4-7.5 (m, 1H), 6.79 (s, 1H), 6.64 (d,
1H, J=8.3 Hz), 5.77 (br s, 1H), 3.4-3.5 (m, 4H), 3.31 (s, 3H), 3.2-3.2 (m, 3H), 2.6-2.7 (m, 3H), 2.5-2.5 (m,
3H), 2.21 (d, 1H, J=16.5 Hz), 1.92 (quin, 2H, J=6.3 Hz), 1.07 (dd, 6H, J=6.1, 12.5 Hz), 0.99 (s, 3H) 13C NMR
(CDCl3, 101 MHz): δ 193.4, 171.3, 151.1, 149.9, 149.0, 142.8, 129.1, 117.2, 112.0, 109.8, 107.0, 72.8,
71.6, 70.2, 58.0, 48.2, 40.1, 40.0, 36.4, 29.2, 23.2, 22.8, 21.9, 13.6. HRMS m/z: [M + H]+ calc’d for
C24H35N4O4 443.2650; Found 443.2672.
3.046E Yield (99.0 %). 1H NMR (CDCl3, 500 MHz): δ 8.05 (br s, 1H), 7.46 (br dd, 1H, J=3.1, 8.3 Hz), 6.71 (s,
1H), 6.56 (br d, 1H, J=8.2 Hz), 6.18 (br s, 3H), 4.03 (q, 1H, J=7.2 Hz), 3.42 (t, 2H, J=5.9 Hz), 3.25 (s, 3H),
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3.21 (br t, 2H, J=6.5 Hz), 3.1-3.2 (m, 3H), 3.07 (br dd, 2H, J=3.5, 6.4 Hz), 2.91 (s, 10H), 2.59 (br d, 2H,
J=16.5 Hz), 2.44 (s, 3H), 2.18 (br d, 1H, J=16.4 Hz), 1.95 (s, 1H), 1.85 (quin, 2H, J=6.3 Hz), 1.7-1.8 (m, 1H),
1.17 (t, 1H, J=7.1 Hz), 0.95 (s, 3H), 0.77 (dd, 6H, J=2.1, 6.8 Hz) 13C NMR (CDCl3, 126 MHz): δ 193.4, 171.6,
151.0, 149.6, 149.0, 142.5, 129.7, 117.1, 112.3, 108.9, 106.1, 78.2, 77.9, 70.2, 60.3, 58.6, 47.9, 42.5,
40.1, 32.4, 29.1, 28.3, 23.2, 19.2, 13.3. HRMS m/z: [M + H]+ calc’d for C25H37N4O4 457.2807; Found
457.2831.
3.046F Yield (23.3 %). 1H NMR (CDCl3, 400 MHz): δ 8.05 (br s, 1H), 7.45 (br d, 1H, J=7.5 Hz), 6.77 (br s,
1H), 6.57 (br d, 1H, J=6.5 Hz), 5.9-6.2 (m, 1H), 3.45 (br s, 6H), 3.1-3.4 (m, 11H), 2.5-2.7 (m, 4H), 2.48 (s,
3H), 2.21 (br d, 1H, J=16.4 Hz), 1.8-2.0 (m, 2H), 0.98 (s, 3H). 13C NMR (CDCl3, 101 MHz): δ 193.2, 171.5,
151.1, 149.8, 148.8, 142.6, 129.5, 117.1, 112.3, 108.9, 106.3, 78.3, 71.8, 70.9, 70.2, 59.0, 58.6, 47.8,
40.1, 32.3, 29.1, 23.1, 13.4, 1.0.
3.046G Yield (19.9 %). 1H NMR (CDCl3, 400 MHz): δ 8.06 (br s, 1H), 7.45 (d, 1H, J=8.4 Hz), 6.79 (d, 1H,
J=1.4 Hz), 6.59 (dd, 1H, J=1.5, 8.3 Hz), 5.6-6.2 (m, 1H), 5.26 (s, 1H), 3.46 (br d, 4H, J=5.9 Hz), 3.36 (s, 2H),
3.30 (s, 3H), 2.62 (d, 2H, J=16.5 Hz), 2.50 (s, 3H), 2.2-2.3 (m, 1H), 1.90 (s, 2H), 1.75 (t, 2H, J=6.3 Hz), 1.00
(s, 3H). 13C NMR (CDCl3, 126 MHz): δ 193.2, 171.5, 151.0, 149.6, 148.8, 142.4, 129.8, 117.0, 112.5, 108.8,
106.1, 77.8, 70.2, 69.4, 68.2, 58.5, 47.8, 42.5, 39.9, 36.1, 32.3, 29.0, 23.2, 13.3.
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Chapter 4: Malaria Treatments
4.1: Start of Project
In addition to our investigation into anti-leishmanial compounds, we pursued an exploration into the
development of molecules to be used for the potential treatment of malaria. While there are effective
treatments available for malaria, there is still great concern about the development of resistance.
Apprehension that our current anti-malarial therapies may no longer be useful has led to an emphasis on
the creation of new molecules to fill these roles.
4.1.1 Heterocycle Introduction
Our group began our search for new compounds to be used as malarial treatments by looking at some of
the original molecules found to show antimalarial activity. These malaria treatments, chloroquine and
primaquine, are derived from quinine and share a common diethylpentane-1,4-diamine side chain.

Figure 4.1 –Malaria Treatments
Mefloquine, another malaria treatment, also contains a segment that mimics the hydrogen-bonding of
this chain. While there have been studies exploring changes to this side chain most do not focus on large
modifications to the quinoline core. No research has been conducted on 4-amino quinazoline analogs of
these structures. As such we wanted to investigate the synthesis of novel heterocyclic rings with the
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common N-linked side chain of chloroquine and primaquine. By creating analogs with alternative
heterocyclic cores, we hope to find compounds that might gain antimalarial activity and / or escape
current resistance. We proposed the use of several heterocycles as shown in Figure 4.2.

4.2 Amine Heterocycle Approach

Figure 4.2 – Proposed Analogs
The compounds we chose contained fused 5 and 6 membered rings versus two fused 6 membered rings
as seen in the quinoline derived analogs. We felt these heterocycles represented diversity that had not
been tested previously while maintaining the 4 nitrogen of the quinoline. We chose in part to explore
heterocycles that replaced a double bond in the 6-membered phenyl ring with sulfur, which has been
known to act as a bio-isostere of a carbon-carbon double bond, and the larger size might mimic the
larger ring.
4.2.1 Retrosynthesis

Figure 4.3 – Retrosynthesis Approach
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We began our exploration of analogs by focusing on a retrosynthesis route (Figure 4.3) that synthesized
the heterocycle core with an amine substituent. This amine could then be used to displace a leaving
group or used to perform a reductive amination on an appropriate ketone to install the side chain.
4.2.2 Synthesis of 5-(diethylamino)pentan-2-ol and derivatives
The synthesis of the amine side chain (Scheme 4.1) commenced with treating 5-chloropentan-2-one
with diethylamine to yield 4.007, which was then reduced with NaBH4 to yield the alcohol 4.009. We also
pursued an alternate route to obtain the alcohol, starting from 5-methyldihydrofuran-2(3H)-one (4.008),
which was treated with diethylamine, DIBAL-H and HCl to also yield 4.009. Once we obtained the
alcohol, we converted it to two different leaving groups using either thionyl chloride to create the alkyl
chloride 4.010 or tosyl chloride and base to create the tosylate 4.011.
Scheme 4.1 – Synthesis of 5-(diethylamino)pentan-2-ol and Derivatives

Reagents and conditions: (a) NHEt2 (83%); (b)NaBH4, MeOH (82%); (c) NHEt2, DIBAL-H, HCl (66%); (d)
SOCl2 (99%); (e) K2CO3, TsCl, TEA (18.5%)
4.2.3 Synthesis Attempts of imidazo[1,2-a]pyrimidine heterocycle
With several options for the amine side chain in hand we began synthesis of the heterocyclic portion of
our analogs. Following Scheme 4.2 for our first heterocycle, imidazo[1,2-a]pyrimidine, we treated
pyrimidine-2,4-diamine with 2-chloroacetaldehyde (4.012) and sodium bicarbonate to yield the amine
heterocycle 4.013.1 In addition to the indicated structure, another constitutional isomer was also
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synthesized as a byproduct. Since it was not clear by NMR which was our desired structure, we carried
both forward in the synthesis.
Scheme 4.2 – Synthesis of imidazo[1,2-a]pyrimidine analog

Reagents and conditions: (a) NaHCO3, 2-chloroacetaldehyde (22%)
Each isomer was used to attempt a reductive animation with the ketone 4.007 synthesized earlier. We
first ran this reaction at 200 °C, which was unsuccessful. Other reaction conditions were attempted
including NaBH4 and NaOH, as well as acetic acid and NaBH4. None of these produced the desired
product 4.001.
4.2.4 Synthesis Attempts of thieno[2,3-b]pyridine heterocycle

Scheme 4.3 – Synthesis of thieno[2,3-b]pyridine analog

Reagents and conditions: (a) NCCH2CN, NEt3 (98%); (b) acetylacetone, pTsOH·H2O (57%); (c) AlCl3, HCl,
PhCl (42%); (d) 4.007, AcOH, NaBH4
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We also began the synthesis of the thieno[2,3-b]pyridine heterocycle following a similar synthesis
outlined in Scheme 4.3.2 The synthesis started by treating 1,4-dithiane-2,5-diol (4.014) with
malononitrile and triethylamine to yield 2-aminothiophene-3-carbonitrile (4.015).3 This compound was
then reacted with pentane-2,4-dione and p-toluenesulfonic acid monohydrate to yield 4.016.4 Treatment
with AlCl3 and HCl in chlorobenzene yielded the desired heterocycle 4.017.2 However the final addition
of the amine side chain (4.007) through reductive animation as well as previously described methods
failed.
4.2.5 Aniline Models
To prevent further loss of our more difficult to synthesize heterocycles, we substituted aniline as a
simple, convenient and inexpensive model system. This model system would allow us to develop the
correct conditions to create the amine bond without using our intermediates. We tried various leaving
groups (Scheme 4.4) such as a chloro group and tosylate. We also tried several bases including
potassium carbonate, triethylamine, and sodium carbonate among others. Unfortunately, all the
conditions we undertook did not result in the formation of the desired amine bond. Additionally, we
attempted reductive amination conditions on a ketone derivative (4.019) and our model aniline (4.007).
These attempts also did not prove effective.
Scheme 4.4 – Aniline Model Reaction Attempts

Reagents and conditions: (a) i) 200 °C ii) NaBH3CN; (b) AcOH, NaBH4 (c) i) 200 °C ii) NaBH4
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4.3. Alcohol Heterocycle Approach
The difficulties we encountered in the formation of the amine bond using of 5-(diethylamino)pentan-2one (4.007) led us to look for an alternative synthetic route. Having encountered trouble using the
leaving group on the side chain, we considered instead using nucleophilic aromatic substitution with the
heterocycle and N1,N1-diethylpentane-1,4-diamine (4.020). We could accomplish this route (Figure 4.4)
by first creating the alcohol of the heterocycle 4.022, which when converted to a chloro group, could be
displaced to obtain the sought-after compound 4.003.

Figure 4.4 – Alternative Retrosynthesis Approach

4.3.1 Synthesis of Thieno[3,2-b]pyridine Analog
We began this route by attempting the synthesis of the thieno[3,2-b]pyridine analog 4.003 following the
route outlined in Scheme 4.5. Our efforts towards this analog began with the formation of the oxalate
salt 4.024, which was achieved by treating methyl 3-aminothiopenen-2-carboxylate (4.023) with NaOH
and ethylene glycol followed by workup with oxalic acid. This was then condensed with
triethylorthoformate and Meldrum’s acid to create intermediate 4.025 which was cyclized at 200 °C to
yield the thienylpyridone 4.021. This compound was then converted to the aryl halide 4.022 using
POCl3.5 The chloro-analog 4.021 was treated with N1,N1-diethylpentane-1,4-diamine (4.020) under
several conditions, with success achieved through the use of Pd(OAc)2, K3PO4 and bis[(2diphenylphosphino)phenyl] ether (DPEPhos) to yield the final product 4.003.
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Scheme 4.5 – Synthesis of thieno[3,2-b]pyridine Analog

Reagents and conditions: (a) oxalic acid, NaOH, ethylene glycol (69%); (b) triethylorthoformate,
Meldrum’s acid, 85 °C, 12h (72%); (c) 200 °C (78%); (d) POCl3 (17%); (e) Pd(OAc)2, K3PO4, DPEPhos

4.3.2 Synthesis of thieno[2,3-b]pyridine Analog

A similar synthesis was attempted to obtain the thieno[2,3-b]pyridine analog outlined in Scheme 4.6.
This began by treating ethyl 2-aminothiophene-3-carboxylate with either KOH or NaOH and oxalic acid to
create 4.026.6 This oxalate salt was similarly treated with Meldrum’s acid and triethylorthoformate in
potassium carbonate to yield the intermediate 4.028. Unfortunately this compound, unlike the previous
synthesis, did not form the desired heterocycle upon heating. We then turned to another synthesis to
reach the molecule beginning by treating 4.030 with diethyl(ethoxymethylene)malonate to yield 4.030.
This diethyl ester was then heated with polyphosphoric acid (PPA) in an unsuccessful attempt to form
4.031.7
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Scheme 4.6 – Attempted Synthesis of thieno[2,3-b]pyridine Analog

.
Reagents and conditions: (a) NaOH, oxalic acid (44%); (b) triethoxymethane, Meldrum’s acid, K2CO3, 85
°C, 12h (21%); (c) 200 °C; (d) diethyl 2-(ethoxymethylene)malonate, KOH, 120 °C (10%) (e) PPA, 140 °C,
1h
After the previous failed attempts at forming the thieno[2,3-b]pyridine analog, we began pursuing
another alternative route. This route outlined in Scheme 4.7 began using thiophen-2-amine as a starting
material. We used multiple reactions to reach this molecule in a form that would proceed successfully in
the following step. We finally found that creating the hexachlorostannate from 2-nitrothiophene was
most successful. This reaction involved treating 4.032 in HCl with tin shavings to yield 4.033.8 This was
then used without purification in a condensation reaction with diethyl 2-(ethoxymethylene)malonate to
yield 4.034. The cyclization of this was followed by heating the reaction in Dowtherm at 200 °C for 1.5
hour to produce 4.035. The ester of this compound was then cleaved with base and heated at 250 °C for
12 hours to achieve the decarboxylated product 4.036. This was treated with POCl3 to substitute the
hydroxyl for the chloro group9 to yield 4.037, which was then used in the final step with 4.020 to attach
the side chain and produce the desired analog 4.004.
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Scheme 4.7 – Synthesis of thieno[2,3-b]pyridine Analog

Reagents and conditions: (a) Sn, HCl (29%); (b) diethyl 2-(ethoxymethylene)malonate (99%) (c) 200 °C
1.5 h (94%); (d) NaOH (77%); (e) 250 °C, 15 min (92%); (f) POCl3 (63%); (g) 4.020, 250 °C, 12 h (11%)
4.3.3 Synthesis of [1,2,4]triazolo[1,5-a]pyrimidine Analog
The syntheses of the remaining two analogs both followed similar procedures (Scheme 4.8 and Scheme
4.9).10 For analog 4.002 the synthesis began with commercially available 4H-1,2,4-triazol-3-amine (4.038)
which was added to concentrated sulfuric acid. To this mixture was added racemic malic acid, which
yielded after workup 4.040, which was then chlorinated using thionyl chloride.10 Finally, the side chain
was installed by heating 4.041 and 4.020 until no starting material remained to yield 4.002.
4.3.4 Synthesis of imidazo[1,2-a]pyrimidine Analog
While the synthesis of our imidazo[1,2-a]pyrimidine analog 4.001 followed very similar conditions to
4.002, the starting material was not as easily obtained. In order to reach 4.044 we heated 4.042 and
4.043 until the evolution of CH3SH ceased, and then the reaction was acidified with H2SO4 to provide the
salt (Scheme 4.9).11 We were also able to obtain this using O-methylisourea as a starting material.12 From
4.044 the synthesis followed the previously discussed synthesis in Scheme 4.8 to obtain 4.001.
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Scheme 4.8 – Synthesis [1,2,4]triazolo[1,5-a]pyrimidine Analog

Reagents and conditions: (a) H2SO4, NaOH (14%); (b) SOCl2 (11%) (c) 4.020 (55%)

Scheme 4.9 – Synthesis imidazo[1,2-a]pyrimidine Analog

Reagents and conditions: (a) H2O, 50 °C, 4 h, H2SO4 (88%); (b) H2SO4, NaOH (32%) (c) SOCl2 (11%) (d)
4.020 (55%)
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4.4 Malaria Conclusions
We have completed the synthesis of four novel structures each of which contain the diethylpentane-1,4diamine side chain found in chloroquine and primaquine as potential antimalarial compounds. These
compounds feature novel heterocyclic cores that have not yet been investigated as for biological activity.
Our samples are scheduled to be tested for antimalarial activity and the results will dictate the
development of further modifications and analogs.

4.5 Experimental Section
General Synthetic Procedures:

Thiophen-3-amine oxalic acid: Into a round-bottomed flask was added aqueous 4N sodium hydroxide
(40 mL, 80 mmol) and methyl 3-aminothiophene-2-carboxylate (6.4 g, 41 mmol) and the mixture was
heated to reflux for 30 minutes. After the reaction was cooled to 0 °C it was adjusted to pH 1 by the
dropwise addition of concentrated H2SO4. The precipitate was collected by vacuum filtration, dissolved in
100 mL acetone, dried over Na2SO4, filtered and concentrated under reduced pressure. The yellow solid
was dissolved in 3 mL 1-propanol and treated with oxalic acid (4.0 g, 40 mmol) then stirred at 40 °C for
45 minutes. The precipitate was isolated by vacuum filtration and washed with 1-propanol then dried
under vacuum to yield 4.024 as a light brown solid (5.3 g, 69 % yield).
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2,2-Dimethyl-5-((thiophen-3-ylamino)methylene)-1,3-dioxane-4,6-dione : Into a round-bottomed flask
was added 4.024 (3.3 g, 18 mmol), and 30 mL of triethylorthoformate under argon and stirred at rt for
15 minutes, then Meldrum’s acid (2.8 g, 19 mmol) was added and the mixture was heated to 85 °C under
argon overnight. A dark brown precipitate formed, and the mixture was cooled to 0 °C and collected
through vacuum filtration. The red brown solids were washed with MTBE, air dried then dried under
vacuum to yield 4.025 as a red brown solid (3.2 g, 72 %). 1H NMR (CDCl3, 500 MHz): δ 11.2-11.4 (m, 1H),
8.4-8.5 (m, 1H), 7.40 (dd, 1H, J=3.2, 5.2 Hz), 7.0-7.1 (m, 2H), 1.75 (s, 6H). 13C NMR (DMSO-d6, 101 MHz):
δ 164.1, 163.2, 154.1, 138.8, 127.8, 121.1, 112.4, 104.4, 86.3, 26.9

Thieno[3,2-b]pyridin-7-ol : Into 1.9 mL of toluene was added 4.025 (0.51 g, 2.0 mmol) and the reaction
was heated to 200 °C for 1 hr and then cooled to RT, diluted with MTBE, and filtered to yield 4.021 as a
dark brown solid (0.24 g, 78 %). 1H NMR (METHANOL-d4, 500 MHz): δ 7.9-8.0 (m, 2H), 7.29 (d, 1H, J=5.4
Hz), 6.36 (d, 1H, J=7.2 Hz)

7-Chlorothieno[3,2-b]pyridine : Into a round bottom was added 4.021 (0.41 g, 2.7 mmol) and 3.8 mL
phosphoryl oxychloride was added slowly at 0 °C. The solution was heated to 90 °C for half an hour. After
the reaction was complete by TLC, the excess POCl3 was removed by reduced pressure and cold
saturated sodium bicarbonate added to quench the reaction at 0 °C. The solution was then extracted
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with DCM, washed with brine, dried over sodium sulfate, filtered, concentrated and stored in an air tight
container flushed with argon in a desiccator to yield 4.022 as a dark oil (0.1909 g, 1.125 mmol, 83%
yield). This product was used without further purification directly in the next step.

N1,N1-Diethyl-N4-(thieno[3,2-b]pyridin-7-yl)pentane-1,4-diamine: In a reaction vial was added
potassium phosphate (0.17 g, 0.82 mmol), (oxybis(2,1-phenylene))bis(diphenylphosphine) (0.01 g, 0.03
mmol), and diacetoxypalladium (2.9 mg, 0.01 mmol). 4.022 (0.08 g, 0.5 mmol) was dissolved in 2 mL of
dioxane and added to the vial along with N1,N1-diethylpentane-1,4-diamine (0.09 mL, 0.49 mmol). The
reaction was heated at 85 °C for 18 hours and the crude product was purified by column
chromatography (silica gel, eluent: 1-6% methanol (containing 10% NH4OH) in DCM) to yield 4.003 as a
white solid (0.03 g, 30 %). 1H NMR (CDCl3, 500 MHz): δ 8.36 (br d, 1H, J=5.4 Hz), 7.54 (d, 1H, J=5.4 Hz),
7.45 (d, 1H, J=5.4 Hz), 6.41 (d, 1H, J=5.4 Hz), 4.31 (br d, 1H, J=7.8 Hz), 3.7-3.8 (m, 1H), 2.52 (q, 4H, J=6.8
Hz), 2.43 (t, 2H, J=6.8 Hz), 2.05 (br d, 1H, J=14.2 Hz), 1.6-1.7 (m, 1H), 1.5-1.6 (m, 3H), 1.30 (d, 3H, J=6.4
Hz), 1.00 (t, 6H, J=7.1 Hz). 13C NMR (CDCl3, 126 MHz): δ 148.7, 148.2, 127.1, 126.3, 99.4, 88.1, 52.4, 48.4,
46.7, 34.6, 22.9, 20.7, 10.9. HRMS m/z: [M + H]+ calc’d for C16H25N3S 292.184; Found 292.1855.
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Bis(2-thienylammonium) hexachlorostannate : To 110 mL of concentrated HCl was added 2nitrothiophene (6.5 g, 50 mmol) and the solution was heated to 40 – 45 °C. Tin shavings (10.7 g, 90
mmol) were added with constant stirring over about 10 minutes. After addition, stirring was continued
without cooling until all the metal had gone into solution. The solution was then cooled, filtered and
washed with ethanol to yield 4.032 as a pale pinkish white crystal (8.57 g, 32.2%) which was used
directly without further purification in the next step.

Diethyl 2-((thiophen-2-ylamino)methylene)malonate : To a stirring solution of diethyl 2(ethoxymethylene)malonate (6.2 mL, 31 mmol) in 85 mL pyridine was added 4.032 (8.6 g, 16 mmol)
portion wise. The reaction was stirred for 24 hours at 40 – 45 °C and then poured onto 12.5 g of crushed
ice. Aqueous ammonia was added until the pH reached 11 and the solution was extracted with
chloroform (3x5 mL). The solution was washed with 10 % CuSO4 solution (2X), then with brine, dried
over Na2SO4, filtered and evaporated under reduced pressure. The crude product was purified by column
chromatography (silica gel, eluent 3/1 hexanes/ethyl acetate) to yield 4.033 as a light pink solid (5.466 g,
99%). 1H NMR (METHANOL-d4, 400 MHz): δ 8.21 (s, 1H), 7.03 (dd, 1H, J=1.3, 5.5 Hz), 6.89 (dd, 1H, J=3.8,
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5.4 Hz), 6.80 (dd, 1H, J=1.3, 3.7 Hz), 4.1-4.3 (m, 4H), 1.3-1.3 (m, 6H). 13C NMR (METHANOL-d4, 101 MHz):
δ 165.9, 153.7, 143.7, 126.2, 118.3, 114.6, 93.0, 59.9, 13.2

Ethyl 4-hydroxythieno[2,3-b]pyridine-5-carboxylate : To 1.9 mL of Dowtherm was added 4.033 (0.10 g,
0.37 mmol) and heated under reflux (200 °C) for 1.5 hours. After cooling the reaction was diluted with
hexanes and the dark solid precipitate was filtered, washed with hexanes and dried to yield 4.035 as a
dark solid (0.08 g, 90 %) 1H NMR (CDCl3, 400 MHz): δ 8.2-8.2 (m, 1H), 6.8-6.9 (m, 1H), 6.6-6.7 (m, 1H),
4.2-4.3 (m, 2H), 1.3-1.4 (m, 3H). 13C NMR (CDCl3, 101 MHz): δ 165.2, 154.2, 143.8, 126.5, 118.1, 114.3,
93.8, 36.7, 14.3.

Thieno[2,3-b]pyridin-4-ol : In 43 mL of ethanol was added 4.035 (0.86 g, 3.9 mmol) and NaOH (0.729 g,
18.2 mmol) (in 5 mL of water) and stirred for 3.5 hours at 100 °C. The reaction was monitored by TLC
(DCM : MeOH, 20:1). The reaction was concentrated, mixed with ice and adjusted to pH <1 with aqueous
HCl. Solids formed were collected by filtration to yield the intermediate 4-hydroxythieno[2,3-b]pyridine5-carboxylic acid (0.58 g, 77%). This intermediate (1.0 g, 5 mmol) was added to 14 mL of Dowtherm
heated at 250 °C for 15 minute intervals until TLC showed complete consumption of starting material
(TLC 9 : 1, DCM : MeOH). The crude product was purified by column chromatography (silica gel, eluent
3/1, Hexanes/Ethyl Acetate) to yield 4.036 as a white solid (0.7411 g, 92%). 1H NMR (400 MHz, CD3OD): δ
7.95 (br d, 1H, J=6.3 Hz), 7.41 (br d, 1H, J=5.7 Hz), 7.29 (br d, 1H, J=5.7 Hz), 6.46 (br d, 1H, J=6.5 Hz).
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4-Chlorothieno[2,3-b]pyridine : Into 2 mL of phosphoryl oxychloride was added 4.036 (0.12 g, 0.77
mmol) at 0 °C. The solution was heated to 90 °C for an hour, and when TLC showed no starting material,
ice cold saturated sodium bicarbonate was used to quench the reaction at 0 °C. The pH was then
adjusted to 8 with 3N NaOH and the solution was then extracted with DCM, washed with brine, dried
over sodium sulfate, filtered and concentrated to 4.037 (0.10 g, 76 %).

N1,N1-Diethyl-N4-(Thieno[2,3-b]pyridin-4-yl)pentane-1,4-diamine : Into a sealed reaction flask was
added 4.037 (0.10 g, 0.58 mmol), N1,N1-diethylpentane-1,4-diamine (0.13 mL, 0.69 mmol) and
triethylamine (0.16 mL, 1.2 mmol) in 2 mL of ethanol and the reaction was heated to 250 °C overnight.
The solvent was removed under reduced pressure and the crude product was purified by column
chromatography (silica gel, eluent: 1-6 % methanol (containing 10% NH4OH) in DCM) to yield 4.004 as a
light tan solid (0.04 g, 24.9 %). 1H NMR (CDCl3, 600 MHz): δ 8.20 (br d, 1H, J=5.4 Hz), 7.65 (br d, 1H, J=5.7
Hz), 7.24 (d, 1H, J=6.0 Hz), 6.33 (br d, 1H, J=5.4 Hz), 3.73 (br s, 1H), 2.9-3.0 (m, 4H), 2.83 (br dd, 1H, J=6.4,
12.9 Hz), 2.1-2.2 (m, 2H), 1.9-2.1 (m, 2H), 1.7-1.9 (m, 3H), 1.2-1.3 (m, 9H). 13C NMR (D2O, 150 MHz): δ
159.8, 145.9, 145.3, 119.7, 117.9, 116.0, 49.6, 45.6, 44.3, 30.6, 27.1, 19.2, 18.2, 6.2.
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[1,2,4]Triazolo[1,5-a]pyrimidin-7-ol : In a round-bottomed flask was added sulfuric acid (10 mL, 200
mmol) and cooled to 0 °C. 4H-1,2,4-Triazol-3-amine (2.03 g, 24.2 mmol) and 2-hydroxysuccinic acid (3.6
g, 27 mmol) were added very slowly to make a thick solution. The solution was stirred at rt overnight and
then heated to 100 °C for 1 hour, then cooled to rt and diluted with ice water. The pH was adjusted to 6
using 6N NaOH solution and extracted with ethyl acetate, then concentrated under reduced pressure.
The crude product was purified by column chromatography (silica gel, eluent: 1-6% methanol
(containing 10% NH4OH) in DCM) to yield 4.040 as a white solid (0.4602 g, 14% yield).

7-Chloro-[1,2,4]triazolo[1,5-a]pyrimidine : Into a round-bottomed flask was added 1.5 mL of SOCl2 and
4.040 (0.20 g, 1 mmol) was slowly added with vigorous stirring. The reaction was stirred under reflux
overnight, then cooled and quenched with cold saturated aqueous NaHCO3. The solution was extracted
with DCM. Then dried with Na2SO4, filtered and concentrated to yield 4.041 as a light tan solid (0.0200 g,
10.9 %) which was used without further purification in the next step.
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N4-([1,2,4]Triazolo[1,5-a]pyrimidin-7-yl)-N1,N1-diethylpentane-1,4-diamine : N1,N1-Diethylpentane1,4-diamine (0.24 mL, 1.2 mmol) and 4.041 (0.02 g, 0.2 mmol) were added to a sealed reaction vial and
heated to 150 °C for 3 hours then allowed to cool. The reaction was concentrated under reduced
pressure then purified by column chromatography (silica gel, eluent: 1-5% methanol (containing 10%
NH4OH) in DCM) to yield 4.002 as a white solid (0.0242 g, 54.6 %). 1H NMR (CDCl3, 400 MHz): δ 8.38 (d,
1H, J=5.6 Hz), 8.26 (s, 1H), 6.80 (br s, 1H), 6.12 (d, 1H, J=5.6 Hz), 3.6-3.8 (m, 1H), 2.51 (quin, 4H, J=6.8
Hz), 2.41 (t, 2H, J=6.9 Hz), 1.6-1.8 (m, 2H), 1.5-1.6 (m, 2H), 1.34 (d, 3H, J=6.5 Hz), 0.97 (t, 6H, J=7.2 Hz).
13

C NMR (CDCl3, 101 MHz): δ 155.8, 154.3, 154.2, 147.3, 88.1, 52.1, 48.7, 46.8, 34.5, 23.4, 20.2, 11.3.

HRMS m/z: [M + H]+ calc’d for C14H25N6 277.2141; Found 277.2151.

1H-Imidazol-2-amine hemisulfate : To 1.7 mL of water was added 2,2-dimethoxyethanamine (1.3 mL, 12
mmol) under inert atmosphere and the solution was heated to 50 °C for 4 hours. The reaction was then
cooled to rt and adjusted to between pH 2 to 5 with 3N sulfuric acid. The solution was then heated to
100 °C and stirred for 2 hours, cooled to rt and slowly dropped over a 1 h period into acetone and stirred
an additional hour at 0 °C. The suspension was then filtered off and washed twice with 0 °C ethanol to
yield 4.044 as a tan solid (0.5 g, 50 %). The product was used without further purification in the next
step.
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Imidazo[1,2-a]pyrimidin-5-ol : To 2.9 mL of concentrated sulfuric acid at 0 °C was added 4.044 (1.0 g, 8
mmol) and 2-hydroxysuccinic acid (1.1 g, 8.5 mmol) very slowly to make a thick solution. The solution
was stirred at rt overnight and then heated to 100 °C for 1 hour. The reaction was allowed to cool to rt
and then diluted with ice water. The pH was adjusted to 6 using 6N NaOH solution, methanol was added
to the solution and precipitation formed and collected. The crude product was then purified by column
chromatography (silica gel, eluent: 1-5% methanol (containing 10% NH4OH) in DCM) to yield 4.045 (0.8
g, 80 %).

5-Chloroimidazo[1,2-a]pyrimidine : Under vigorous stirring was added 4.045 (0.8 g, 6 mmol) to 4.5 mL
of phosphoryl oxychloride and the mixture was heated to reflux for 18 hours. After cooling the mixture
was added portion wise to 1 mL of ice water and adjusted to a pH of 12 with 6N aqueous NaOH and
extracted with ethyl acetate. Then organic layer was then dried with Na2SO4, filtered and concentrated to
yield 4.046 as a brown oil (0.5 g, 60 %) which was used without further purification in the next step.

N1,N1-Diethyl-N4-(imidazo[1,2-a]pyrimidin-5-yl)pentane-1,4-diamine : To N1,N1-diethylpentane-1,4diamine (2.460 mL, 12.70 mmol) was added 4.046 (0.25 g, 1.7 mmol) in a sealed reaction vial and the
reaction was heated to 150 °C for 3 hours. The reaction was concentrated under reduced pressure then
purified by column chromatography (silica gel, eluent: 1-5% methanol (containing 10% NH4OH) in DCM)
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to yield 4.001 as a white solid (0.44 g, 97.0 %). 1H NMR (CDCl3, 400 MHz): δ 8.19 (br d, 1H, J=5.2 Hz), 7.85
(br s, 2H), 7.7-7.8 (m, 1H), 7.48 (br s, 1H), 5.91 (d, 1H, J=5.4 Hz), 3.68 (br d, 1H, J=5.3 Hz), 2.48 (q, 5H,
J=6.9 Hz), 2.37 (br t, 2H, J=6.7 Hz), 1.5-1.8 (m, 4H), 1.29 (d, 3H, J=6.4 Hz), 0.95 (t, 7H, J=7.1 Hz). 13C NMR
(CDCl3, 101 MHz): δ 150.7, 147.4, 132.6, 106.0, 86.0, 53.4, 52.3, 49.0, 46.8, 34.2, 23.6, 20.1, 11.2
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Appendix – I
Biological Assays
Leishmaniasis
All data was obtained using 96-well plates. Control compounds were used in order to ensure proper
assay behavior. Data from assays are reported as the average of three consecutive readings (N=3) with
variability typically in the range of less than +/- 10%. Miltefosine and Radiciol were obtained from
commercial sources (Sigma-Aldrich) and was used as acquired.
L. donovani axenic amastigote assay
L. donovani axenic amastigotes were seeded at a concentration of 106 parasites/mL in 96-well
plates in the presence or absence of compounds of interest. Test compounds were serially diluted in 100
μL of PBS. Ten μl of each well was transferred to another 96 well plate and then receives 90 μl or
parasites in media and then 20 μL of the commercially available CellTiter reagent (a water soluble
tetrazolium dye from Promega) was added. After a 3-4 h incubation period at 37 °C to allow for reduction
of the dye, to achieve conversion of the color from purple to yellow, the absorbance of each well was
measured at 490 nm using a SpectraMax Plus microplate reader (Molecular Devices). The results were
presented as the percentage of survivors (OD value with test compound divided by that of untreated
control). IC50 values were determined with the aid of a four-parameter, logistic dose response equation
in the DataAspects Plate Manager software. Curve fitting using non-linear regression was done using
trifox to obtain IC50 values.
Hsp 90 Assay
The Hsp90 fluorescence polarization assay was conducted in the laboratory of Gabriela Chiosis using the
procedures described in their manuscript and using compound PU-H71 as a control compound (Kim, J.;
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Felts, S.; Llauger, L.; He, H.; Huezo, H.; Rosen, N.; Chiosis, G. Development of a fluorescence polarization
assay for the molecular chaperone Hsp 90. J. Biomol. Screening 2004, 9, 375-381).
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